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Abstract

The liver is the most common site of metastasis in cancer. While this metastatic tropism may reflect trapping
of tumor cells that enter the circulation, mechanistic basis for the propensity of tumor cells to metastasize to
the liver remains ill-defined. Here, we show using the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre
(KPC) mouse model of pancreatic adenocarcinoma (PDAC) that primary tumor development enhances the
susceptibility of the liver to metastatic colonization by establishing a “pro-metastatic” niche in the liver. This
niche is notable for accumulation of myeloid cells and extracellular matrix proteins, including fibronectin. 3’
mRNA sequencing of RNA isolated from the liver of KPC mice versus control LSLTrp53R172H/+;Pdx-1-Cre (PC) mice revealed that the liver produces a specific set of myeloid
chemoattractants, particularly serum amyloid A1 and A2 (SAA), early during tumorigenesis. In addition, gene
set enrichment analysis (GSEA) on genes upregulated in the liver of KPC mice demonstrated a significant
enrichment of the interleukin 6 (IL-6)/Signal Transducer and Activator of Transcript 3 (STAT3) signaling
pathway. Consistent with this finding, phosphorylation of STAT3 was detected in 80-90% of hepatocytes. We
determined a requirement for IL-6/STAT3/SAA signaling in the formation of a pro-metastatic niche by
comparing the metastatic potential of wild type mice, Il-6 knockout (Il-6-/-) mice, and mice that lack Stat3
specifically in hepatocytes (Stat3flox/flox Alb-Cre) after orthotopic implantation of KPC-derived PDAC
cells. Compared to wild type mice, the liver of Il-6-/- mice and Stat3flox/flox Alb-Cre mice was less
susceptible to metastatic colonization and showed significantly less accumulation of myeloid cells, fibrosis,
and production of SAA in the liver. Further, using Saa knockout (Saa-/-) mice, we found that SAA production
by hepatocytes was required for the formation of a pro-metastatic niche in the liver and increased
susceptibility to metastatic colonization. Many patients with a history of locally advanced and metastatic
disease showed elevated levels of circulating SAA, which were correlated with worse overall survival. SAA
overexpression was also detected in hepatocytes in liver biopsy samples collected from PDAC and colorectal
cancer patients. Collectively, our data identify hepatocytes as a key driver of liver metastasis and reveal new
therapeutic targets for cancer.
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ABSTRACT
HEPATOCYTE-DRIVEN REGULATION OF LIVER METASTASIS
Jae W. Lee
Gregory L. Beatty

The liver is the most common site of metastasis in cancer. While this metastatic
tropism may reflect trapping of tumor cells that enter the circulation, mechanistic basis for
the propensity of tumor cells to metastasize to the liver remains ill-defined. Here, we show
using the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mouse model of pancreatic
adenocarcinoma (PDAC) that primary tumor development enhances the susceptibility of
the liver to metastatic colonization by establishing a “pro-metastatic” niche in the liver.
This niche is notable for accumulation of myeloid cells and extracellular matrix proteins,
including fibronectin. 3’ mRNA sequencing of RNA isolated from the liver of KPC mice
versus control LSL-Trp53R172H/+;Pdx-1-Cre (PC) mice revealed that the liver produces a
specific set of myeloid chemoattractants, particularly serum amyloid A1 and A2 (SAA),
early during tumorigenesis. In addition, gene set enrichment analysis (GSEA) on genes
upregulated in the liver of KPC mice demonstrated a significant enrichment of the
interleukin 6 (IL-6)/Signal Transducer and Activator of Transcript 3 (STAT3) signaling
pathway. Consistent with this finding, phosphorylation of STAT3 was detected in 80-90%
of hepatocytes. We determined a requirement for IL-6/STAT3/SAA signaling in the
formation of a pro-metastatic niche by comparing the metastatic potential of wild type mice,
Il-6 knockout (Il-6-/-) mice, and mice that lack Stat3 specifically in hepatocytes (Stat3flox/flox
Alb-Cre) after orthotopic implantation of KPC-derived PDAC cells. Compared to wild type
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mice, the liver of Il-6-/- mice and Stat3flox/flox Alb-Cre mice was less susceptible to metastatic
colonization and showed significantly less accumulation of myeloid cells, fibrosis, and
production of SAA in the liver. Further, using Saa knockout (Saa-/-) mice, we found that
SAA production by hepatocytes was required for the formation of a pro-metastatic niche
in the liver and increased susceptibility to metastatic colonization. Many patients with a
history of locally advanced and metastatic disease showed elevated levels of circulating
SAA, which were correlated with worse overall survival. SAA overexpression was also
detected in hepatocytes in liver biopsy samples collected from PDAC and colorectal cancer
patients. Collectively, our data identify hepatocytes as a key driver of liver metastasis and
reveal new therapeutic targets for cancer.
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CHAPTER 1: Introduction
Pancreatic ductal adenocarcinoma
Incidence.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer
deaths in the United States. In 2018, the estimated incidence of PDAC was 55,440 cases,
and over 44,000 of patients died from the disease1. Despite recent advances in cancer
treatments, including radiation and immunotherapies, PDAC remains incurable with a
median survival of six months2. High mortality in PDAC is, at least in part, attributable to
the lack of specific symptoms and diagnostic tests that can be utilized for early detection
of the disease. Common symptoms of PDAC include vague abdominal discomfort, dull
abdominal pain, and nausea. Patients may also display systemic symptoms, including
anorexia and weight loss, as well as jaundice and ascites. However, these symptoms are
not specific to PDAC, and routine blood tests typically do not reveal abnormalities besides
mild aberrations in liver-function tests, hyperglycemia, and anemia2.
High frequency of metastatic disease is another factor contributing to high mortality
in PDAC. At presentation, nearly 70% of patients are diagnosed with metastatic disease
that most commonly affects the liver followed by the peritoneum and lung3. The remaining
30% of patients who are diagnosed with locally advanced disease usually undergo surgical
resection with curative intent, but recurrence is common. A recent study demonstrated that
PDAC recurred in 70% of patients who underwent resection, with the liver as the most
common site of recurrence (47%)4. Taken together, effective diagnostic tests as well as
therapeutic strategies that inhibit metastasis may lead to a major improvement in the
clinical outcome of PDAC.
1

Mutations.
Found in 80% to 90% of human pancreatic tumors, the KRAS proto-oncogene is the
most commonly mutated gene in PDAC5-7. Activating point mutations in KRAS typically
occur at codon 12, resulting in a single amino-acid change from glycine to aspartic acid
(KRASG12D). These mutations lead to constitutive activation of KRAS, which promotes
proliferation and transformation of pancreatic cells. Gene dosage of mutant KRAS is also
correlated with pancreatic tumorigenesis and metastasis8. Other commonly mutated genes
in PDAC are TP53, SMAD4, CDKN2A, and ARID1A. Together, these mutations alter
cellular processes involved in apoptosis, proliferation, cell cycle transition, differentiation,
and axonal guidance5,6. Consequently, clinically relevant mouse models of PDAC, which
are discussed in Chapter 2, incorporate these mutations and target them to the pancreas. In
addition, emerging data highlight the importance of mutations in the tumor antigen MUC16
in driving anti-tumor T cell responses9.

Classification.
Whole-genome sequencing and copy number variation analysis have recently
revealed that the genomic landscape of PDAC is complex and displays a wide range of
chromosome structural variations7. Based on these findings, PDAC was classified into four
subtypes: stable (≤ 50 structural variation events), locally rearranged (focal events on one
or two chromosomes), scattered (moderate range of chromosome damage and < 200
structural variation events), and unstable (≥ 200 structural variation events). In another
study, gene expression microarray data sets generated from resected PDAC tissues were
used to classify PDAC10. This analysis revealed 62 genes that distinguished three subtypes
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of PDAC: classical, quasimesenchymal, and exocrine-like. The classical subtype was
associated with adhesion and epithelial genes, while the quasimesenchymal and exocrinelike subtypes displayed mesenchymal-associated genes and digestive enzyme genes,
respectively. Subtypes of PDAC demonstrated differences in clinical outcome as well as
chemosensitivity. Evidence for subtypes in PDAC was further corroborated by another
study that relied on high throughput RNA sequencing to identify four subtypes of PDAC:
pancreatic progenitor, immunogenic, squamous, and aberrantly differentiated endocrine
exocrine (ADEX)11. Collectively, these studies suggest that PDAC is a complex disease
defined by heterogeneous levels of chromosomal instability and gene expression.

Metastatic spread of PDAC
Pro-metastatic niche.
Metastasis is a multi-step process. Traditional model of metastasis posits that
primary tumor cells must grow and invade the vasculature, where single tumor cells or
aggregates detach and enter the circulation. Tumor cell then become embedded in the
capillary beds of distant organs, where tumor cells undergo extravasation, invade into the
distant organ parenchyma, and proliferate. According to this model, metastatic disease may
affect virtually all organs in the body. However, metastatic disease most commonly affects
the liver and lung, and mechanisms underlying this metastatic tropism have long remained
a mystery. Although the liver and lung may act as a “mechanical trap” that captures
circulating tumor cells12, emerging evidence suggests that primary tumor development also
induces dynamic alterations in distant organs to establish a “pro-metastatic niche” that
supports tumor cell colonization and growth. Key features of this niche are myeloid cells
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and the local stromal microenvironment that suppress anti-tumor immune responses and
enhance tumor cell seeding and growth13.
The formation of a pro-metastatic niche has been studied most extensively in
experimental models of melanoma and lung and breast carcinomas13, but recent studies
have suggested that this process also occurs in PDAC. Costa-Silva et al. and Hoshino et al.
proposed that pancreatic tumor cells secrete exosomes that express macrophage migration
inhibitory factor (MIF) and integrin αvβ5 into the circulation14,15 (Fig. 1.1). Exosomes are
subsequently taken up specifically by liver-resident macrophages and induce production of
transforming growth factor beta (TGF-β) within the liver. TGF-β then stimulates hepatic
stellate cells to deposit fibronectin within the liver and in doing so, promote myeloid cell
accumulation and tumor cell seeding. However, these studies have an important caveat that
exosomes were derived from the PAN02 cell line, which was developed by implantation
of cotton thread-carrying 3-methylcholanthrene into the pancreas of a C57BL/6 mouse16.
In contrast to human pancreatic cancer cells, the PAN02 cell line lacks KRAS, TP53, and
CDKN2A mutations17, which are recognized as “driver mutations” in pancreatic cancer. In
addition, exosomes were injected at supraphysiological doses (5 µg of exosomes every
other day, 3 times a week) to establish a pro-metastatic niche in the liver.
Tissue inhibitor of metalloproteinases 1 (TIMP1) has also been proposed to regulate
the formation of a pro-metastatic niche in the liver (Fig. 1.1). Grünwald et al. and Seubert
et al. suggested that tumor cells may release TIMP1, which binds CD63 on hepatic stellate
cells18,19. This process induces hepatic stellate cells to express CXCL12, which promotes
neutrophil recruitment into the liver in a CXCR4-dependent manner. Genetic ablation of
Timp1 and its receptor Cd63 inhibited activation of hepatic stellate cells and reduced the
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susceptibility of the liver to metastatic spread. Based on studies on TIMP1 as well as
exosomes, hepatic stellate cells have emerged as a key driver of liver metastasis. However,
our understanding of mechanisms underlying the formation of a pro-metastatic niche in the
liver remains incomplete. In Chapters 3 and 4, we describe hepatocyte-driven regulation of
the formation of a pro-metastatic niche in the liver and discuss therapeutic strategies to
inhibit this process in Chapter 5.

Metastatic niche.
Myeloid cells and the local stromal microenvironment that define the formation of
a pro-metastatic niche in the liver continue to have a major role in regulating metastasis
even after tumor cells seed and proliferate within the liver. Macrophages that associate with
metastatic tumor cells have been proposed to secrete granulin, which induces hepatic
stellate cells to differentiate into myofibroblasts that produce periostin20. Subsequently,
periostin sustains a fibrotic microenvironment that supports the growth of metastatic tumor
cells. Disruption of macrophage recruitment and genetic ablation of granulin reduced
activation of hepatic stellate cells and liver metastasis. As metastatic lesions grow, lesions
become hypovascular and continue to accumulate a desmoplastic stroma as well as myeloid
cells21. Metastatic lesions eventually develop a microenvironment that resembles the
primary tumor in terms of differentiation and immune cell composition. Hence, myeloid
cells and the stroma are critical determinants and integral to all phases of liver metastasis.
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Figure and figure legend

Figure 1.1 | Formation of a pro-metastatic niche in the liver. Recent studies proposed
that pancreatic tumor cells secrete exosomes and TIMP-1 into the circulation. Exosomes
are taken up by liver-resident macrophages, which in turn produce TGF-β. Subsequently,
TGF-β stimulates hepatic stellate cells to deposit fibronectin. In addition, TIMP-1
stimulates hepatic stellate cells to release CXCL12, which induces myeloid cell recruitment
into the liver. Together, these processes establish a pro-metastatic niche in the liver.
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CHAPTER 2: The KPC Model, Its Variants, and Their Application in
Immuno-Oncology Drug Discovery
The contents of this chapter have been published:
Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. & Beatty, G. L. Genetically
engineered mouse models of pancreatic cancer: the KPC model (LSL-KrasG12D/+;
LSL-Trp53R172H/+;Pdx-1-Cre), its variants, and their application in immunooncology drug discovery. Curr. Protoc. Pharmacol. 73, 14.39.1–14.39.20 (2016).

Abstract
Pancreatic ductal adenocarcinoma (PDAC) ranks third among cancer-related deaths
in the United States. For patients with unresectable disease, treatment options are limited
and lack curative potential. Preclinical mouse models of PDAC that recapitulate the
biology of human pancreatic cancer offer an opportunity for the rational development of
novel treatment approaches that may improve patient outcomes. With the recent success of
immunotherapy for subsets of patients with solid malignancies, interest is mounting in the
possible use of immunotherapy for the treatment of PDAC. Considered in this chapter is
the value of genetic mouse models for characterizing the immunobiology of PDAC and for
investigating novel immunotherapeutics. Several variants of these models are described,
all of which may be used in drug development and for providing information on unique
aspects of disease biology and therapeutic responsiveness.
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Introduction
Immunotherapy has demonstrated significant benefit for the treatment of some
patients with advanced cancer. Most notably, immune checkpoint inhibitors that target
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)22-24 and the programmed cell death
protein 1 pathway (PD-1/PD-L1)25-32 produced major tumor regressions leading to durable,
long-term responses in a subset of patients. For example, in metastatic melanoma ~20% of
patients respond to therapeutic blockade of CTLA-4 with remissions lasting >5 years24.
However, while these responses to immunotherapy can be robust and may lead to improved
overall survival, not all patients respond to this treatment, and positive responses are often
transient33. Thus, in non-small cell lung cancer, the response rate with anti-PD-1 blockade
with nivolumab is ~19%, with a 12.5 month median duration of response27. Similarly, in
advanced renal cell carcinoma, the response rate to nivolumab was 25%, with a median
progression-free survival of 4.6 months30. This immune resistance that is especially evident
in PDAC in which immunotherapies have not yet reliably produced clinical benefit34,35
despite promising findings demonstrating the potential of harnessing the immune system
in this condition28,36. The biology that underlies the poor responsiveness of PDAC and
other malignancies to immunotherapy remains ill-defined. As a result, studying immune
resistance mechanisms exploited by cancer is critical to designing and testing immunetargeted strategies capable of affecting the natural progression of this almost uniformly
lethal disease.
Prior to the development of genetically engineered mouse models of PDAC, tumor
transplantation models were employed for investigating the ability of immunotherapy to
impact tumor growth in vivo. Transplantation models utilize human or mouse pancreatic

8

cancer cells that are implanted into recipient mice. For example, in a xenograft model
system, human pancreatic tumor cell lines are implanted into mice via subcutaneous,
intravenous, peritoneal, or orthotopic injection37,38. This approach makes it possible to
investigate in vivo the biology of human PDAC cells and to assess the responsiveness of
PDAC to cytotoxic therapies. However, to avoid immune rejection of human tumor cells
transplanted into a different species, xenograft models require the use of immunodeficient
mice. Thus, a major drawback of this model is the lack of a competent immune system,
thereby limiting its value as a tool for investigating immunotherapeutics. Moreover, tumor
cells used in these xenograft models are often passaged extensively in vitro thereby limiting
tumor cell clonal heterogeneity and, therefore, their potential biological relevance.
While the development of patient-derived xenograft tumor models39 and
humanized mice40 has made it possible to preserve many features of tumor heterogeneity
and to introduce human leukocyte populations, respectively, these models are challenging
logistically and costly to produce. A mainstay in the study of cancer immunology has been
the use of murine-derived cancer cell lines implanted into syngeneic mice. Unlike
xenograft models, syngeneic mice are immunocompetent, which makes it possible to
examine immune mechanisms of anti-tumor immunity and immune resistance. However,
most transplantation models do not model precisely tumor development and the induction
of immune tolerance that occurs in patients. In fact, the mere implantation of tumor cells,
often passaged extensively in vitro, can induce a “vaccine effect" leading to immune
activation and alterations of the tumor microenvironment that may not be characteristic of
the human disease41. For example, tumor cells commonly grow more slowly when
implanted into immune competent mice compared to immunodeficient mice42. This reflects
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the capacity of cancer cells to adapt to immune pressure, a process termed immunoediting,
in which cancer clones that acquire the capacity to evade immune elimination emerge and
dominate tumor outgrowth43.
For these reasons, and those described below, genetically engineered mice that
spontaneously develop PDAC are of particular value for immunotherapeutic drug
discovery because the tumors develop in the context of a competent and fully intact
immune system. However, there are significant challenges with genetically engineered
mice as well. These relate to their use and maintenance as well as to the interpretation of
findings given the stochastic and heterogeneous nature of tumors that arise
spontaneously44-46. Described below is the use of genetic mouse models of PDAC and some
variants in the development of immunotherapeutic drugs for the treatment of this condition.

Genetic mouse models of PDAC
Analyses of tumor samples collected from patients have revealed that the genomic
landscape of PDAC is complex, being characterized by high chromosomal instability and
frequent alterations in a select group of genes, including KRAS, TP53, SMAD4, CDKN2A,
and ARID1A, with relatively few somatic coding mutations7. Based on this knowledge,
multiple mouse models of PDAC have been developed. The reader is referred to several
recent reviews that discuss in detail the development of these models which incorporate
alterations in proto-oncogenes (e.g., KRAS) and tumor suppressor genes (e.g., TP53,
SMAD4, and CDKN2A) that are targeted specifically to the mouse pancreas47,48. Two of
the most commonly mutated genes in PDAC are the KRAS proto-oncogene and the TP53
tumor suppressor gene5-7,49. KRAS mutations are found in 80% to 90% of all human
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PDACs with mutations in TP53 detected in 50% to 75% of these patients. Consequently,
one of the most studied genetically engineered mouse models of PDAC incorporates
mutations in Kras and Trp53 that are targeted specifically to the mouse pancreas using CreLox technology44.
The information provided in this unit is focused on the LSL-KrasG12D/+;LSLTrp53R172H/+;Pdx-1-Cre (KPC) mouse model of PDAC as a platform for investigating
immunotherapy because (i) it reproduces many of the key features of the immune
microenvironment observed in human PDAC, including a robust inflammatory reaction
and exclusion of effector T cells; (ii) it is the most extensively studied genetic model of
PDAC for evaluation of immunotherapy; and (iii) it reproduces clinical responses observed
in PDAC patients treated with several immuno-oncology drugs, including CD40 agonists
and anti-PDL1 antibodies46,50-53. The approaches described for studying immunotherapy
and the immunobiology of PDAC may also be applied to other PDAC models, as well. The
reader is referred to recent reviews for a more complete discussion on other genetically
engineered mouse models of PDAC54,55.
The KPC mouse model of PDAC was first described in 2005. It incorporates,
through Cre-Lox technology, the conditional activation of mutant endogenous alleles of
the Kras and Trp53 genes44. Specifically, an activating point mutation (G12D) in Kras and
a dominant negative mutation in Trp53 (R172H) are conditionally activated in the mouse
pancreas by breeding LSL-KrasG12D/+;LSL-Trp53R172H/+ mice to Pdx-1- Cre mice that
express Cre recombinase under the expression of the pancreas-specific Pdx-1 promoter.
The Cre-mediated recombination acts to excise the loxP-flanked stop codon (LSL), an
event that occurs only in cells expressing Cre, leading to conditional expression of mutant
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Kras and Trp53 genes specifically in the mouse pancreas.
The routine breeding of KPC mice requires first crossing LSL-KrasG12D/+ (K/+)
mice with LSL-Trp53R172H/+ (P/+) mice to generate LSL-KrasG12D/+;LSL-Trp53R172H/+
(K/+P/+) offspring (Fig. 2-1a). K/+P/+ mice are then crossed with P/+ mice to generate
LSL-KrasG12D/+;LSL-Trp53R172H/R172H (K/+P/P) animals. While both K/+P/+ and K/+P/P
male mice may be used to cross with homozygous Pdx-1-Cre female mice to generate KPC
offspring, the efficiency of this cross with K/+P/P mice is increased two-fold, making it
the preferred breeding strategy (Fig. 2-1a). However, maintenance of K/+P/P mice is
challenging given their shortened lifespan (range 10 to 20 weeks of age) and the tendency
of these animals to develop tumors (e.g., lymphoma) due to homozygous inactivation of
the Trp53 gene.
The original KPC model was produced on a mixed genetic background (129/Sv and
C57BL/6)44. Each of the three strains of mice (i.e., K/+, P/+, and Pdx-1-Cre mice) are
commercially available on this mixed background from the Jackson Laboratory (LSLKrasG12D, stock no: 008179; LSL-Trp53R172H, stock no: 008652; Pdx-1 Cre, stock no:
014647) and NCI Mouse Repository (LSL-KrasG12D, strain no: 01XJ6; LSL-Trp53R172H,
strain no: 01XAF; Pdx-1 Cre, strain no: 01XL5). All three strains of mice have been
backcrossed in our laboratory to the C57BL/6J genetic background for at least ten
generations. In doing so, we have not observed any compromise in tumor penetrance,
kinetics of disease onset, or the phenotype of lesions that emerge, such as their propensity
to metastasize. Moreover, a pure genetic background makes it possible to conduct adoptive
cell transfer studies (i.e., the transfer of cells from one mouse to another, including the
transfer of cells that have been altered or engineered to display novel properties)56.
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Recently, Stromnes et al. (2015)53 investigated the adoptive transfer of T cells as a novel
immunotherapeutic approach for the treatment of PDAC in KPC mice. These types of
studies are essential for defining the immune mechanisms of action and for evaluating
novel therapies, such as engineered T cells.
The KPC model has significant advantages over xenograft and implantation models
of PDAC. First, the KPC model recapitulates many of the salient clinical (e.g., ascites
development, bowel and biliary obstruction, and cachexia) and histopathological features
(e.g., cellular morphology, poor vascularity, fibrosis, and metastatic spread) of the human
disease44,46,50,57-59. Second, because KPC mice are immunocompetent they provide a useful
platform for studying interactions between the immune system and tumor cells. In
particular, the tumor microenvironment in the KPC model demonstrates a striking
inflammatory infiltrate with a scarcity of effector T cells46,51,52,60. Because this
characteristic of tumors in KPC mice mirrors observations in human PDAC, this model
offers

an

opportunity

to

understand

mechanisms

driving

inflammatory

cell

recruitment/biology and T cell exclusion. Third, in contrast to xenograft and syngeneic
transplantation models of PDAC, tumors arise spontaneously in KPC mice, with
development of defined histopathologic stages of progression that mirror human
disease44,49,61. Lastly, low passage tumor cell lines can be derived readily from tumorbearing KPC mice for use in in vitro and in vivo drug development screens50,52,57,60.
The KPC mice display disease progression that closely resembles the human
condition (Fig. 2-1b). The pancreas of newly born KPC mice is normal and devoid of
neoplastic cells (Fig. 2-1c). However, by 8 to 10 weeks of age, KPC mice harbor precursor
lesions, or pancreatic intraepithelial neoplasia (PanIN), within the pancreas (Fig. 2-1c). At
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this early stage of PDAC development, a strong inflammatory response marked by
infiltration of F4/80+ cells is seen that persists from disease conception through invasion
and metastasis (Fig. 2-1d). In addition, during PanIN progression, single pancreatic cells
undergo an epithelial-to-mesenchymal transition in which cells lose epithelial markers,
such as E-cadherin, upregulate mesenchymal markers, such as Zeb1 and Fsp1, and become
more spindle- and fibroblast-like in their morphology. With this transition, pancreatic cells
can also undergo hematogenous dissemination with rare single pancreatic cell detection in
the liver62. This process is promoted by the inflammatory reaction associated with the
disease62. However, the precise mechanisms by which inflammatory cells regulate
pancreatic cancer metastasis remain ill-defined. Nonetheless, similar findings occur in
patients with pancreatic cystic lesions in the absence of an obvious clinical diagnosis of
cancer63. Together, these findings suggest that hematogenous dissemination of malignant
cells in PDAC may occur early during disease progression and might potentially explain
the high relapse rate in patients undergoing surgical resection with curative intent64-66.
By 16 weeks of age, most KPC mice develop locally invasive PDAC accompanied
by a dense desmoplastic reaction. At this time the majority of mice show evidence of tumor
development and biliary obstruction as detected by abdominal ultrasonography. With
disease progression, mice can also develop cachexia, jaundice, weight loss, and malignant
ascites due to peritoneal spread of the disease. In addition, PDAC tumors that arise
spontaneously in KPC mice can metastasize to other organs including the liver, lymph
nodes, lung, diaphragm, and adrenal glands (Fig. 2-1c)44. This tendency of PDAC to
metastasize, and the anatomic distribution of metastases seen in the KPC model, mirrors
tumor dissemination in human PDAC. Therefore, this model makes possible detailed
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investigations into the biology of PDAC metastasis.
Genetic variants of the KPC model have been developed to study malignant cell
invasion and metastasis in PDAC. While these models show a similar disease phenotype,
including the kinetics of disease onset, they incorporate lineage tracing markers, such as
yellow fluorescent protein (YFP). For example, by including an LSL-Rosa26-YFP
transgene into the KPC model to generate KPCY mice, cells of the pancreata (both benign
and malignant) can be monitored by YFP expression62. With this approach, circulating
YFP+ pancreatic cells have been detected in the KPCY mice beginning early during PDAC
development, with their frequency increasing with disease progression and inflammation.
A variant of this strategy has also been developed to enable a multicolor lineage tracing
system to monitor the clonality of metastatic lesions67. This approach uses a “Confetti”
lineage labeling system, in which Cre-mediated recombination produces stochastic
expression of one of four fluorescent proteins in a cell. Findings from these mice, termed
“KPCX,” suggest that PDAC metastases may be polyclonal, and they support a role for
clonal diversity in the evolution of metastatic disease.
This observation has profound implications regarding the potential intra- and interlesional clonal heterogeneity of PDAC lesions. For example, individual PDAC lesions in
KPC mice almost invariably demonstrate a non-uniform distribution of leukocytes such
that some regions of a tumor may show an increased presence of leukocyte populations
whereas other areas may be completely devoid of cellular subsets (e.g., eosinophils).
Likewise, tumor cell morphology and fibrosis deposition can vary significantly across
individual lesions (i.e., intra-lesional heterogeneity). This variability is also seen between
lesions (i.e., inter-lesional heterogeneity) even within the same host44. While the
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therapeutic implications of this heterogeneity remain unknown in PDAC, it may explain
the variability of treatment responses with some therapeutics, such as chemotherapy in
combination with a CD40 agonist68.
The KC model is another variant of the KPC model. The KC model results from
the incorporation of only an activating point mutation (G12D) in Kras that is conditionally
expressed in the pancreas due to Cre recombinase expression driven by the pancreasspecific Pdx-1 promoter61. In KC mice, the full spectrum of disease from PanIN to invasive
PDAC can be observed, although disease progression is slower with only a subset of mice
showing progression to invasive and metastatic cancer by 1 year of age61. Nonetheless,
these mice are particularly useful for evaluating the development of precursor PanIN
lesions and for developing strategies to delay progression to invasive PDAC. From these
studies, components of the immune system, including IL-6, STAT3, and myeloid cells,
have been identified as critical determinates for driving PanIN to PDAC progression69-71.

Immunobiology of human and mouse PDAC
Genetically engineered mouse models of PDAC provide an opportunity to
investigate cross-talk between the immune system and neoplastic cells from disease
conception through invasion and metastasis. These models can also be used to investigate
the impact of immunotherapy at multiple stages of disease pathogenesis with the intent to
(1) prevent disease occurrence; (2) delay the progression of precursor lesions to invasive
cancer; and (3) treat local and metastatic disease. However, the value of these models for
these purposes is predicated on their capacity to reproduce the human immunobiology.
The immunobiology of human PDAC has mainly been studied using primary
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pancreatic tissue obtained at the time of surgery from patients presenting with surgically
resectable disease72-76. Thus, analysis of the immune microenvironment has largely been
restricted to a small subset (20%) of those diagnosed with this condition. From these studies,
the immune microenvironment of PDAC has been found to be complex, with multiple
leukocyte populations present including macrophages, neutrophils, eosinophils, and mast
cells. The degree of recruitment of these cell types can also vary significantly among
tumors. Lymphocytes, including B and T cells, can also be found within some PDAC
lesions although their presence is often confined to the tumor margin and is sometimes
limited to clustering rather than diffuse infiltration. This general exclusion of T cells from
the bulk of the tumor tissue is consistent with the premise that PDAC is a poorly
immunogenic tumor capable of establishing a site of immune privilege52. This contrasts
with tumors commonly classified as “immunogenic,” such as melanoma and renal cell
carcinoma, where effector T cell infiltration of tumor tissue is more often observed.
Because developing tumors in KPC mice have a tendency to metastasize, KPC mice
can be used to investigate the immunobiology of primary and metastatic lesions. In contrast,
obtaining sufficient material to investigate leukocyte recruitment and biology in primary
and metastatic lesions from patients with surgically unresectable PDAC is difficult due to
poor anatomic accessibility of the lesions and the limited material that can be obtained from
a core biopsy. As a result, information is lacking about the immunobiology of PDAC and
the degree of heterogeneity that may exist between lesions even in the same patient. Such
biology can be more readily performed in genetic mouse models of PDAC.
The PDAC lesions arising spontaneously in the KPC mouse model reproduce the
leukocyte complexity observed in human PDAC46,50,52,60. As with the human disease,
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primary PDAC lesions in KPC mice display an infiltration of F4/80+ macrophages (Fig. 22a, c). Myeloid cells can be found in close proximity to PDAC cells. Their phenotype,
however, is dependent on their surrounding microenvironment such that many cellular
subsets are likely to be present within tumors despite the common tendency in the literature
to describe these cells based on a few surface markers (e.g., CD11b, F4/80, Gr- 1, MHC II,
CD206, CD163) and the presence or absence of molecules (e.g., iNOS and Arg1) that are
associated with findings observed primarily in in vitro culture conditions (e.g., M1 versus
M2 macrophages)77. In general, it is thought that myeloid cells associated with PDAC, as
with other solid malignancies, act to enhance tumor growth and metastasis by promoting
tumor cell migration and invasion into local tissues71.
In contrast to the aggressive recruitment of myeloid cells to tumors, T cell infiltrates
are seen less frequently (Fig. 2-2a, c), with few effector T cells capable of recognizing and
eliminating tumor cells. Of the T cell subsets found, Foxp3+ regulatory T cells (Tregs) are
most prevalent and are commonly observed infiltrating precursor PanIN lesions51. In
addition, IL-17 secreting CD4+ T cells and γδT cells78 have been identified in the
desmoplastic reaction that surrounds PanIN lesions79. Together, these T cell subsets are
implicated as key promoters of PanIN initiation and progression to PDAC because of their
capacity to be immunosuppressive and to provide growth factors (e.g., IL-17) for PanIN
development. For example, Tregs are well-recognized for their ability to suppress tumorspecific T cell immunity by releasing immuno-suppressive cytokines (e.g., IL-10 and TGFβ) that impede effector T cell activity80,81. Moreover, inhibiting the activity of IL-17
producing cells using IL-17 antagonists and by depleting Tregs in combination with a
vaccine has been shown to be efficacious in genetic models of PDAC51,79. Together, these
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findings provide a strong rationale for the development of therapies aimed at redirecting
the immune response to PDAC and have provided important insights into a role for the
natural immune reaction to PDAC in promoting rather than inhibiting disease progression.
In our investigation of metastatic liver lesions detected in KPC mice, we have found
that the leukocyte composition of metastases is similar to the primary tumor and marked
by an abundance of F4/80+ macrophages and few effector T cells (Fig. 2-2b, d). These
findings are consistent with recent reports suggesting that primary and metastatic lesions
in human PDAC appear histologically similar82. In our studies, we have also found that the
capacity of PDAC to exclude T cells appears to be cell intrinsic, as T cell exclusion is
observed in tumors arising from KPC-derived tumor cell lines (1) implanted
subcutaneously (Fig. 2-3a, d); (2) injected orthotopically into the pancreas (Fig. 2-3b, e);
and (3) injected intrasplenically as a model of liver metastasis (Fig. 2-3c, f). Thus, the
capacity of PDAC to establish a site of immune privilege52 may be, at least in part, cancer
cell intrinsic and maintained even during metastasis.
This phenomenon of immune privilege (i.e., the capacity to exclude T cells and/or
evade immune elimination) can also be seen in many other malignancies, such as
colorectal83 and ovarian cancers84. Several mechanisms are proposed to explain the lack of
T cell infiltration into solid malignancies, including insufficient T cell priming, lack of
strong immunogenic antigens capable of being recognized by effector T cells, recruitment
of regulatory cell populations (e.g., Tregs and myeloid suppressor cells), and alterations in
tumor vasculature that prevent T cell extravasation into tissues85. Understanding these
mechanisms has significant clinical implications.

19

Immuno-oncology discovery using genetic models of PDAC
The KPC mice can be used in a variety of ways to investigate the immunobiology
of PDAC. For example, to study the evolution of immune responses during PDAC
progression, mice can be evaluated at 4 to 6 (early PanIN), 8 to 10 (late PanIN), and 16 to
20 (PDAC and metastases) weeks of age. The most common method for monitoring tumor
development in KPC mice involves the use of ultrasonography, which is both cost-effective
and non-invasive45. Ultrasonography provides a high-resolution view of the entire
abdominal cavity and makes it possible to quantify tumor volumes. This approach can be
used to evaluate 4 to 6 KPC mice per hour. However, when applied to a large mouse colony,
this strategy may become time consuming and might require dedicated facilities. As a result,
alternative approaches may be necessary for individual laboratories seeking to incorporate
this model into their studies. For this reason, it is common practice to screen mice weekly
by monitoring their weight and palpating their abdomen to detect the presence of a tumor
prior to ultrasound analysis. As tumors do not typically become apparent by
ultrasonography until 12 to 14 weeks of age, screening is usually initiated at that time.
The use of KPC mice in studies resembles a clinical trial. This is because of (1) the
stochastic nature of PDAC development in KPC mice; (2) the complicated breeding
strategy that is unlikely to produce sufficient numbers of mice to fill all experimental
groups at the time the experiment is initiated; and (3) the need to incorporate eligibility
criteria for mice to be enrolled in the study. For these reasons, KPC mice are enrolled into
studies on a rolling basis. At the onset of a study, eligibility criteria must be defined and
mice block randomized into experimental groups to prevent bias. Examples of eligibility
criteria used for KPC mice with advanced PDAC include ultrasound evidence of a tumor
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measuring 50 to 150 mm3 and age >10 weeks. Mice are excluded from enrollment if they
demonstrate significant comorbidities, including >10% weight loss, weakness, or evidence
of a non-pancreatic tumor such as lymphoma, sarcoma, or hepatocellular carcinoma.
In addition to defining eligibility criteria, end-of-study criteria must also be
determined beforehand. For example, treatment studies can be conducted that assess
response rate and/or survival. Window studies assessing the impact on tumor progression
evaluated at one or two time points after treatment may be necessary if therapy cannot be
administered repeatedly. In contrast, survival studies that simplify the need for serial
imaging analysis can also be used and should incorporate specific endpoints and censoring
criteria. For example, a KPC mouse may develop a sarcoma or lymphoma during the course
of treatment requiring euthanasia for reasons other than pancreatic tumor progression. In
addition, IACUC guidelines define clear criteria for euthanasia, which must be considered
in the study design. Finally, similar to a clinical trial, the impact of a treatment can be
evaluated in KPC mice by repeated peripheral blood analysis and serum collection. This
offers the opportunity to identify potential pharmacodynamic markers that may yield
insights into treatment efficacy, mechanism of action, and potentially useful biomarkers.
For example, Faca et al. (2008)86 used a genetic mouse model of PDAC to conduct a mouse
to human search of plasma proteins associated with pancreatic tumor development. In
addition to blood-derived samples, tissues can also be collected from mice. Tissues, as well
as cells, RNA, and DNA isolated from these tissues, can either be analyzed in real-time or
preserved for later analysis.
Characterization of the immune microenvironment of tumors in mice has
historically involved flow cytometry to detect lymphocytes (e.g., CD19+ B cells and CD3+
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T cells including CD4+ , CD8+, and FoxP3+ T cell subsets) and myeloid cells (e.g., F4/80+
macrophages and CD11b+ Gr-1+ granulocytes and immature myeloid cells). With the
ability now to conduct multicolor flow cytometry, a detailed characterization of the
phenotype of these leukocyte populations (i.e., surface molecule expression, signaling
pathway activation, and cytokine production) is feasible. However, this approach can
sometimes yield misleading results, particularly for tumors that develop spontaneously.
For example, tumors arising in KPC mice often metastasize to the lymph nodes where they
form tumors that are then encased with a rim of lymphoid tissue.
Developing tumors may also encapsulate lymph nodes such that separation of
lymphoid tissue from a tumor is impossible. Thus, while flow cytometric analysis of PDAC
tumors may reveal an abundance of lymphoid cells in tumor tissue, histological
examination may demonstrate a lack of lymphocyte infiltration into tumors with their
presence confined to peritumoral lymph nodes. This precise scenario was seen in the
analysis of CD40 immunotherapy in KPC mice in which it was initially concluded that
CD40 therapy induces potent activation of T cells in tumor tissue46. However, on
histological examination it became apparent that activated T cells were not present within
tumors, but rather were localized to adjacent lymph nodes. For this reason, it is
recommended that immunohistochemistry or immunofluorescence microscopy be used to
complement studies using flow cytometry when investigating leukocyte infiltration into
PDAC.

The value of genetic models for evaluating immunotherapy in PDAC
The potential of immunotherapy to provide clinical benefit for patients with PDAC
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has been observed in several clinical studies. For example, the results of a multicenter,
randomized, phase II study revealed that an allogeneic whole tumor cell vaccine (GVAX)
combined with a mesothelin-specific Listeria-based vaccine improves the overall survival
of PDAC patients with chemotherapy-refractory disease87. In addition, GVAX, in
combination with anti-CTLA-4 immunotherapy, has produced signs of clinical benefit in
a subset of PDAC patients36. The immunological significance of these findings is
strengthened by evidence demonstrating that GVAX vaccination in combination with antiCTLA-4 therapy induces T lymphocyte infiltration into tumors and the development of
tertiary-lymphoid aggregates suggestive of anti-tumor immune activity76.
Macrophages, immature myeloid cells, and granulocytes infiltrate PDAC and can
be supportive of tumor progression and metastasis. Strategies to deplete these cells, block
their recruitment to tissues, or modify their biology are being evaluated preclinically as
well as in ongoing clinical trials88. In contrast, the exclusion of T cells from PDAC tumors
poses a significant challenge to T cell immunotherapy, which relies on the capacity of
tumor-specific T cells to infiltrate tumor tissue and then to recognize and lyse malignant
cells. Thus, poor infiltration of T cells into PDAC lesions may explain the lack of efficacy
observed thus far with immune checkpoint inhibitors.
The ability of the KPC model to mirror the human immunobiology underlying
PDAC is the basis for its value in studying immunotherapy, including strategies to
modulate the inflammatory reaction to PDAC and to induce tumor-specific T cell immune
responses. Genetically engineered mouse models can be used to conduct “co-clinical” trials
in which therapeutic interventions administered to KPC mice match the treatment design
of an ongoing clinical trial in patients. The KPC model has been used in combination with
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a clinical trial to inform the mechanistic underpinnings of tumor responses to
immunotherapy with an antagonistic CD40 antibody46,68. An obvious advantage of the
KPC model compared to a clinical trial is the ability to include appropriate treatment
control groups and to conduct mechanistic studies. Using this approach of simultaneous
human and mouse studies, a CD40 agonist was found to induce peripheral blood monocytes
to acquire anti-tumor and anti-fibrotic properties leading to tumor regressions in both KPC
mice and humans46. This represented a novel mechanism of action for CD40 antibodies,
which are best known for their ability to “license” antigen presenting cells with T cell
stimulatory properties89-91.
The KPC mouse model has also reproduced immunotherapy results reported for
patients with PDAC. For example, limited efficacy in human PDAC has been observed
with single agent immunotherapies, including anti-PD-L1 and anti-CTLA-4 antibodies34,35.
Feig et al. (2013)50 reported that anti-PD-L1 and anti- CTLA-4 antibodies also fail to affect
tumor progression in KPC mice. We have similarly found that treatment of KPC mice with
an anti- PD-1 antibody either alone or in combination with gemcitabine has no impact on
tumor outgrowth (Fig. 2-4). These similarities between mice and humans in the
responsiveness of PDAC to immunotherapy strengthens the appeal of the KPC model as a
tool for defining immune mechanisms that may regulate T cell exclusion and for strategies
to convert PDAC into an immunogenic tumor.
The ability to restrict the infiltration of T cells into tumor tissue has been studied in
the KPC model. One mechanism identified involves chemokine (C-X-C motif) ligand 12
(CXCL12), which is produced by fibroblasts within the tumor microenvironment. By
binding to its receptor, CXCR4 (which is present on tumor cells), CXCL12 is believed to
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inhibit T cell entry into PDAC in the KPC model50. In this study AMD3100, a CXCR4
inhibitor, induced T cell infiltration into PDAC and acted synergistically with an anti-PDL1 antibody to induce rapid tumor regressions in KPC mice. Based on this finding, an
ongoing clinical trial is investigating continuous infusion of AMD3100 in patients with
advanced PDAC (NCT02179970). Overall, these findings suggest the potential importance
of the tumor microenvironment in restricting T cell infiltration into tumor lesions. However,
leukocytes present outside of the tumor microenvironment may also be involved in actively
establishing PDAC as a site of immune privilege.
To this end, we recently reported that the infiltration of T cells into PDAC can be
regulated by extratumoral macrophages52. Depletion of macrophages residing outside of
the tumor microenvironment using clodronate-encapsulated liposomes (CEL) was found
to induce T cell infiltration into PDAC lesions, and—when administered in combination
with gemcitabine chemotherapy and a CD40 agonist—T cell-dependent tumor regressions
were observed in KPC mice. These two studies highlight the potential of the KPC model
for studying T cell exclusion and strategies to enhance the potential of immunotherapy in
PDAC. Findings discovered in KPC mice may also have implications beyond PDAC given
that other solid malignancies, such as ovarian cancer84 and colorectal cancer83, at times
demonstrate T cell exclusion and often display the strong inflammatory reactions that are
hallmarks of the KPC model.

Application of genetic models of PDAC and their variants to preclinical development
of immunotherapy
Because of the complexity of the KPC model, including breeding, the heterogeneity
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of tumors, and the stochastic nature of PDAC development, many investigators have
sought alternative approaches to genetic mouse models of PDAC, including orthotopic92
and subcutaneous implantation models52,93 as well as intrasplenic and intravenous injection
models of metastasis14,94. These models most commonly utilize PDAC cell lines that are
either obtained commercially or are derived from syngeneic genetic models of PDAC.
Tumor organoids can also be established from primary tumors and used in an orthotopic
or subcutaneous implantation model95,96. In addition, pieces of primary tumor tissue can be
excised and re-implanted into syngeneic mice52. These approaches can be cost-effective,
and, while they do reduce the degree of tumor heterogeneity seen between mice in a group,
they can still maintain a significant degree of tumor clonal diversity.
The immunobiology of PDAC implantation models using low-passage tumor cell
lines derived from primary tumors arising spontaneously in KPC mice is similar in many
aspects to the parental primary tumors. For example, histological analysis reveals that
implanted PDAC tumors demonstrate similar levels of fibrosis (Fig. 2-5) and leukocyte
infiltration as those seen in primary tumors in the KPC model (Figs. 2-2 and 2-3). As a
result, these models may be used to study how (1) tumors regulate T cell exclusion; (2) the
myeloid compartment can be redirected to modulate the tumor microenvironment
including vascularity and fibrosis; and (3) tumors adapt to immune pressure.
Tumor cell lines derived from KPC mice are poorly immunogenic. As such, their
in

vivo

growth

rates

in

immunodeficient

and

immunocompetent

mice

are

indistinguishable97. This contrasts with results reported for other more highly mutated
tumors used to establish the concept of immunoediting, a dynamic process in which tumor
cells react to selective immune pressure by decreasing their immunogenicity leading to an
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acquired resistance to immune-mediated elimination98. Furthermore, this observation
raises the possibility that the biology of some tumors, such as PDAC, which harbor few
somatic mutations, may be more appropriately studied using genetic models that lack an
abundance of somatic mutations. One argument against this theory is the potential
importance of neoantigens derived from somatic mutations, which may serve as
immunogenic targets necessary for the success of currently available immunotherapeutic
maneuvers. Neoantigens are proteins that become mutated during tumor development and
that lead to novel peptide sequences recognized by the immune system as foreign, thereby
enhancing the immunogenicity of a cancer cell99. However, shared antigens (i.e., nonmutated self-proteins that may be overexpressed or aberrantly expressed in tumor cells),
while potentially less immunogenic than neoantigens, may also serve as immune
targets76,87,100. We and others have found that T cells can be induced to mediate anti-tumor
activity in the KPC model, which is based on only two mutations50-53. However, the
antigens targeted by T cells in PDAC remain ill-defined.
We have studied five routes of implantation of KPC-derived tumor cell lines,
including subcutaneous, intravenous, intrasplenic, intraperitoneal, and orthotopic to
investigate the impact of anatomic location on the immunobiology of PDAC and to develop
models that can provide information on the role of immunotherapy aimed at targeting
PDAC lesions residing in distinct anatomic compartments (Fig. 2-6). The major strength
of subcutaneous injection over other routes of tumor cell implantation is the ease of this
procedure and the ability to monitor tumor development and growth using calipers. While
PDAC tumors rarely metastasize to the skin in patients, this strategy can be useful for
examining mechanisms and potential efficacy of immunotherapy. In addition, because
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tumors implanted subcutaneously can metastasize to the lung, this model is useful for
studying PDAC lung metastasis.
Orthotopic implantation of PDAC cells is an attractive alternative to subcutaneous
implantation because tumors will arise in their native organ and will metastasize to distant
sites. However, monitoring of tumors implanted orthotopically requires imaging strategies
similar to those used with the KPC model, such as ultrasonography. Bioluminescence
imaging can also be incorporated by engineering PDAC cell lines to express a luciferase
reporter (Fig. 2-7). An advantage of bioluminescence is the ability to investigate the impact
of therapeutic intervention on tumor viability rather than only tumor size, which in PDAC
includes not only cellular content but also fibrosis.
Intravenous, intraperitoneal, and intrasplenic routes of administration of PDAC cell
lines can be used to model lung metastasis, peritoneal and lymph node metastasis, and liver
metastasis, respectively. With intrasplenic injection, we have used both ultrasound guided
injections into the spleen and direct implantation involving surgery. Both strategies
produce liver metastases. However, while the non-invasiveness of ultrasound-guided
injections is attractive, peritoneal drop metastases can occur along with the tumor lesions
in the spleen. These issues can be obviated by direct intrasplenic injection followed by
surgical removal of the spleen. With this approach, tumor cells will exit the spleen via the
splenic vein, enter the portal vein, and deposit in the liver forming metastases.
With each of these implantation models, we have found that the histological
appearance and leukocyte complexity of developing tumors is similar to parental tumors
arising spontaneously in KPC mice. These models also offer the opportunity to investigate, under controlled conditions, the capacity of immunotherapy to target PDAC in
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distinct anatomic locations where the phenotypic characteristics of the immune response
may differ, although leukocyte recruitment is similar. In addition, tumor cell lines can be
genetically manipulated using Cas9/CRISPR technology or other gene knockdown
approaches (e.g., shRNA) to study the role of tumor-derived molecules in regulating the
immune system and the efficacy of immunotherapy60.
It is important to understand that the responsiveness of implantable and genetic
mouse models of PDAC to immunotherapy may vary dramatically despite the ability of
tumors in both models to exclude T cells and recruit a powerful inflammatory response.
For example, we have found that a vaccine including gemcitabine chemotherapy and a
CD40 agonist induces T cell-dependent tumor regression of subcutaneously injected KPCderived tumor cell lines and KPC-derived primary tumor tissue52. However, when this
vaccine strategy is applied to KPC mice with spontaneously arising tumors, regressions are
observed that are dependent on macrophages and can occur even in the absence of T cells.
Together, these models of PDAC reveal distinct mechanisms whereby the same
immunotherapeutic approach may impact PDAC biology. However, when this treatment is
administered to patients, findings suggestive of a T cell independent mechanism of action,
similar to that seen in KPC mice, were observed46,68.
While these findings provide further validation for the KPC model of PDAC, it
does not dismiss entirely the potential utility of implantable models of PDAC. In contrast,
we propose that implantable models are useful for studying how PDAC may adapt to
immune pressure imposed by tumor-specific T cells. In addition, we have found that
implantable models are valuable for studying the capacity of macrophages to be redirected
to alter the tumor microenvironment, in particular the fibrotic reaction that surrounds
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PDAC which is preserved in implantable models (Fig. 2-5). However, if a therapy is being
evaluated for potential use in the clinic, we recommend that findings observed in
implantable models be validated in a genetically engineered mouse model. Indeed, it is
becoming more common for investigators to conduct initial mechanistic studies in
implantable models of PDAC, with validation of findings and correlatives in a genetically
modified animal, such as the KPC model.

Conclusions
Translation of laboratory findings into the clinic is benefited by a preclinical cancer
model that can provide reliable information on the therapeutic efficacy and mechanism of
action. The KPC and other genetic models of PDAC are valuable tools for studying
immunotherapy and the immunobiology of PDAC given their ability to reproduce salient
features of disease progression as seen in humans, including the immune reaction. The
PDAC that arises in the KPC model reproduces a dense desmoplastic reaction infiltrated
by myeloid cells with rare penetrance by effector T cells. Because malignant cells in KPC
mice metastasize to organs, as seen in the human disease, this model offers an opportunity
to study the immunobiology and its diversity in lesions that are often difficult to assess in
patients. Overall, the immune reaction to PDAC as revealed by genetic models of this
disease appears primarily supportive of tumor development and progression.
The KPC model can be used to dissect immune mechanisms of action, to evaluate
the efficacy of immunotherapies designed to modulate the immune microenvironment of
PDAC, and to harness immune effectors. Multiple variants of the KPC model, including
high-throughput implantable models, can be incorporated to establish a pipeline approach
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to drug discovery and development. Thus, the KPC model and similar genetic models,
despite lacking a high mutation burden and the potential for abundant neoantigens,
represent practical and reproducible systems for the discovery and evaluation immunooncology therapeutics.
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Figures and figure legends

Figure 2.1 | KPC murine model of spontaneous PDAC. a, Breeding strategy for
generation of KPC mice. b, Disease progression in KPC mice. c, Histology (40× field) of
(i) normal pancreas, (ii) pancreas of a 10-week-old KPC mouse showing PanIN (iii)
primary pancreatic tumor, and (iv) liver and (v) lymph node showing metastatic tumor.
Images representative of at least 5 mice per group. Dashed lines indicate PanIN in image
(ii) and metastatic tumor in image (iv). d, Two color immunohistochemistry to demonstrate
the spatial relationship between epithelial cells (EpCAM, brown) and macrophages (F4/80,
black) in (i) normal pancreas, (ii) PanIN, (iii) PDAC, and metastatic lesions including (iv)
liver and (v) an adjacent pancreatic lymph node.
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Figure 2.2 | Primary and metastatic tumors in KPC mice show a strong recruitment
of F4/80+ myeloid cells with a weak infiltration of CD3+ T cells. Representative
immunohistochemistry images (40× field) showing F4/80, CD3, CD4, CD8, and FoxP3
staining of (a) primary pancreatic tumor and (b) metastatic tumor in the liver of KPC mice.
Quantification of cell types identified in (c) primary pancreatic tumor (n = 4 to 5 per group)
and (d) metastatic tumor in the liver (n = 4 per group). Scale bars, 100 µm.
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Figure 2.3 | Leukocyte infiltration in implantable models of PDAC. Low-passage KPCderived PDAC cell lines were injected subcutaneously (SQ), orthotopically (OT), or
intrasplenically (IS) into syngeneic C57BL/6J mice (6 to 8 weeks of age). Shown are
representative immunohistochemistry images (40× field) showing F4/80, CD3, CD4, CD8,
and FoxP3 staining from an (a) SQ tumor, (b) OT tumor arising in the pancreas, and (c) IS
tumor that deposited in the liver. Quantification of leukocyte subsets detected by
immunohistochemistry in (d) SQ tumor, (e) OT tumor, and (f) IS tumor (n = 4 per group).
Scale bars, 100 µm.

34

Figure 2.4 | Effect of PD-1 blockade on tumor growth in KPC mice. a, Schematic of
study design. Tumor-bearing KPC mice were randomized into 3 groups: Group 1 (n = 19),
no treatment; Group 2 (n = 4), anti-PD-1 antibody (clone RMP1-14, 0.2 mg IP twice
weekly); and Group 3 (n = 4), gemcitabine (120 mg/kg IP once) plus anti-PD-1 antibody.
Tumor size was assessed by ultrasound on days 0 and 13 after treatment. b, Representative
ultrasound image of primary pancreatic tumor in KPC mice. Ultrasonography was
performed as previously described (Beatty et al., 2011; Sastra and Olive, 2013). Yellow
dashed lines identify tumor border and white dashed lines indicate normal organs and blood
vessels (Ao, aorta; IVC, inferior vena cava; PV, portal vein). c, Fold change in tumor size.
NS, not significant by unpaired two-tailed Student’s t test. IP, intraperitoneal injection.

35

Figure 2.5 | Tumor-associated fibrosis in primary and metastatic tumors in KPC mice
and in implanted tumors. a, Representative Masson’s trichrome stain (40× field) of
primary (left) and metastatic (right) tumor in KPC mice (n = 4 to 5 per group). b,
Representative Masson’s trichrome stain (40× field) of SQ (left) and OT (middle) tumors,
and metastatic tumor in the liver (right). Scale bars, 100 µm.
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Figure 2.6 | Implantation models of PDAC using KPC-derived tumor cell lines. a,
Table showing various implantation models based on multiple routes of injection of KPCderived PDAC cell lines, including subcutaneous (SQ), orthotopic (OT), intraperitoneal
(IP), intravenous (IV), and intrasplenic (IS) routes of injection. b, Representative images
of (i) SQ tumor, (ii) normal pancreas with adjacent spleen of a control mouse (left) and
pancreatic tumor with adjacent spleen from OT injected mouse (right), and (iii) normal
liver from control mouse (left) and liver with numerous metastases from IS injected mouse
(right). Scale bars, 1 cm. Arrows indicate tumor mass.
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Figure 2.7 | Bioluminescence imaging (BLI) for monitoring PDAC growth. Syngeneic
C57BL/6J mice were injected intrasplenically with PBS or 5 × 105 cells from a KPCderived PDAC cell line engineered to express luciferase (PDAC.luc). Mice were imaged 3
weeks post-injection as previously described (Beatty et al., 2011; Sastra and Olive, 2013).
a, Representative ultrasound images of intrasplenic injection of tumor cells into the spleen,
(i) pre- and (ii) post-injection. b, Representative in vivo BLI images. For BLI imaging, Dluciferin substrate was injected intraperitoneally and images were acquired 15 min postinjection using the Perkin Elmer IVIS Spectrum. c, Representative ex vivo BLI images of
the liver.
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CHAPTER 3: Hepatocytes Orchestrate the Formation of a ProMetastatic Niche in the Liver
The contents of this chapter have been published:
Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H.,
Delman, D., Graham, K., Gladney, W. L., Hua, X., Black, T. A., Chien, A. L.,
Majmundar, K. S., Thompson, J. C., Yee, S. S., O’Hara, M. H., Aggarwal, C., Xin,
D., Shaked, A., Gao, M., Liu, D., Borad, M. J., Ramanathan, R. K., Carpenter, E.
L., Ji, A., de Beer, M. C., de Beer, F. C., Webb, N. R. & Beatty, G. L. Hepatocytes
direct the formation of a pro-metastatic niche in the liver. Nature (2019).

Abstract
The liver is the most common site of metastatic disease in gastrointestinal
malignancies, including pancreatic ductal adenocarcinoma (PDAC)2. While this metastatic
tropism may reflect mechanical trapping of tumor cells that enter the circulation, liver
metastasis is also dependent, at least in part, on the formation of a “pro-metastatic” niche
that supports tumor cell seeding and colonization in the liver101,102. Mechanisms that direct
the formation of this niche, though, are poorly understood. Here, we show that hepatocytes
coordinate the accumulation of myeloid cells and fibrosis within the liver, the two defining
features of a pro-metastatic niche, and in doing so, increase the susceptibility of the liver
to metastatic seeding and growth. Early during pancreatic tumorigenesis in mice,
hepatocytes demonstrate activation of Signal Transducer and Activator of Transcription 3
(STAT3) signaling. This cellular activation is dependent on interleukin 6 (IL-6) that is
released into the circulation by non-malignant cells that reside adjacent to malignant cells
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in the pancreas. Genetic ablation or blockade of components of IL-6/STAT3 signaling in
hepatocytes effectively prevents the establishment of a pro-metastatic niche and inhibits
metastatic seeding and growth in the liver. Collectively, our data reveal an intercellular
network underpinned by hepatocytes that forms the basis for a pro-metastatic niche in the
liver and identify new therapeutic targets for pancreatic cancer.

Introduction
Liver metastasis is a major cause of morbidity and mortality in cancer patients.
Compared to other distant organs where metastatic disease is known to occur, the liver is
by far the most frequent site of metastasis in gastrointestinal malignancies103. Because of
the dual blood supply of the liver provided by the portal vein and hepatic artery, the liver
has been proposed to act as a mechanical trap that captures circulating tumor cells and in
doing so, becomes a nidus for metastatic disease12. Conversely, recent studies have
demonstrated that liver metastasis is dependent not only on the anatomic architecture of
the liver but also on the formation of a pro-metastatic niche that supports tumor cell seeding
and growth in the liver101,102. In PDAC, primary tumor cells have been proposed to secrete
soluble factors, including exosomes14,15 and tissue inhibitor of metalloproteinases 1
(TIMP1)18,19, that engender myeloid cell accumulation and fibrosis to establish a prometastatic niche in the liver. However, mechanisms that direct the formation of this niche
remain ill-defined. Better understanding of the impact of primary tumor development on
the liver, particularly the relationship between biological processes that become activated
in the liver and metastasis, may provide insights into mechanisms underlying metastatic
tropism of pancreatic cancer.
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Results
Primary PDAC development induces a pro-metastatic niche in the liver
To understand mechanisms by which malignant cells induce the formation of a prometastatic niche in the liver, we utilized the LSL-KrasG12D/+;LSL-Trp53R127H/+;Pdx-1-Cre
(KPC) mouse model of PDAC44,104. We first examined for key features of a pro-metastatic
niche in the liver of tumor-bearing KPC mice (TB mice) and 8- to 10-week-old KPC mice,
which lack histological evidence of PDAC but harbor pancreatic intraepithelial neoplasia
(non-tumor-bearing mice (NTB mice))62. In NTB KPC mice, tumor cells are virtually
absent in the liver62. Compared to control mice (wild type or LSL-Trp53R127H/+;Pdx-1-Cre
mice), both NTB and TB KPC mice demonstrated increased numbers of F4/80+ and Ly6G+
myeloid cells in the liver, which was accompanied by an increase in the deposition of
extracellular matrix proteins, including fibronectin (FN) and type I collagen (COL1) (Fig.
3.1a and Fig. 3.2a, b). Orthotopic implantation of KPC-derived PDAC cells into wild type
mice also induced these changes in the liver (Fig. 3.2c-g), demonstrating that primary
tumor development can alter the immune and fibrotic microenvironment of the liver.
Similar to prior studies18,19, we also found that myeloid cell depletion using clodronateencapsulated liposomes did not alter matrix deposition in the liver in the setting of primary
tumor development indicating that liver fibrosis occurs independently of phagocytic cells
(Fig. 3.3). Together, these results are consistent with recent studies that have defined
myeloid cell accumulation and extracellular matrix deposition as key components of a prometastatic niche in the liver14,15,18,19.
We next evaluated the susceptibility of the liver to metastatic colonization. To do
so, YFP-labeled KPC-derived PDAC cells (PDAC-YFP)62 were intrasplenically injected
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into syngeneic control mice and NTB KPC mice, both of which lacked endogenous
expression of YFP. Metastatic burden, defined by YFP expression, in the liver was then
quantified by flow cytometry, and was found to be three-fold higher in KPC mice compared
to control mice (Fig. 3.1b, c). By immunohistochemistry, metastatic lesions were detected
in the liver of KPC mice at increased frequency and size, and malignant cells displayed
enhanced proliferation (Ki-67) (Fig. 3.4a-d). Similar findings were observed using a YFPnegative KPC-derived cell line injected intrasplenically into KPC and control mice (Fig.
3.4e-h). We found that orthotopic injection of PDAC cells versus PBS also increased the
susceptibility of the liver to metastatic colonization with enhanced malignant cell
proliferation (Fig. 3.4i-m). Together, these data are consistent with the notion that the liver
is altered early during pancreatic tumorigenesis to favor metastatic seeding and growth.
T cells are recognized as important contributors to tumor development, progression,
and metastasis. Presence or absence of specific T cell subsets within the primary tumor as
well as metastatic lesion has been shown to have prognostic values105. In our studies,
however, primary tumor development showed minimal impact on the percentage of CD4+
and CD8+ T cells that are present in the liver. We also found that the percentage of naïve
(CD44- CD62L+), central memory (CD44+ CD62L+), and effector/effector memory subsets
(CD44+ CD62L-) of CD4+ and CD8+ T cells in the liver remained the same regardless of
primary tumor development. In addition, depletion of CD4+ and CD8+ T cells prior to
intraportal injection of tumors did not affect metastatic colonization of the liver (Fig. 3.5el). These results do not support a role for T cells in establishing the formation of a prometastatic niche in the liver.
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IL-6 is necessary for the establishment of a pro-metastatic niche in the liver
To identify genes that regulate the establishment of a pro-metastatic niche in the
liver, we performed QuantSeq 3’ mRNA sequencing on RNA isolated from the liver of
control mice and NTB KPC mice. Our analysis revealed distinct clustering of genes from
control mice versus KPC mice regardless of gender (Fig. 3.1d) and identified 275
differentially expressed genes (Table 3.1). Gene ontology analysis using the
ClueGO/CluePedia Cytoscape application showed that genes upregulated in the liver of
KPC mice were predominantly associated with immune-related processes, including
inflammatory responses, cell chemotaxis, regulation of defense response, regulation of
chemokine production, and regulation of leukocyte apoptotic process (Fig. 3.1e). Notably,
inflammatory responses and cell chemotaxis encompassed the most number of genes (Fig.
3.1e). Our analysis also revealed a set of myeloid chemoattractants that were upregulated
in the liver of KPC mice (Fig. 3.1f and Fig. 3.6), including Saa1 and Saa2 (Saa) as well as
S100 genes that have been shown to promote lung metastasis in non-pancreatic cancer
models106-108. Together, our results demonstrate that the formation of a pro-metastatic niche
in the liver is associated with a coordinate induction of inflammatory processes.
Inflammatory signaling pathways are central to the pathogenesis and progression
of liver diseases109. To determine pathways that direct the establishment of a pro-metastatic
niche in the liver, we conducted gene set enrichment analysis on genes upregulated in the
liver of KPC mice and found a significant enrichment of the IL-6/JAK/STAT3 signaling
pathway (Fig. 3.7a), in addition to other immune-related pathways (Table 3.2). We
validated our results by examining the liver of NTB and TB KPC mice for the presence of
phosphorylated STAT3 (pSTAT3). Based on a previous study that defined STAT3
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signaling in myeloid cells as an important determinant of a pro-metastatic niche in the
lung110, we first examined F4/80+ myeloid cells for pSTAT3 expression. In both groups of
KPC mice, 20-35% of F4/80+ myeloid cells were positive for pSTAT3, while < 2% of
F4/80+ myeloid cells showed cellular activation in control mice (Fig. 3.8a, b). Remarkably,
we also found that 80-90% of hepatocytes displayed STAT3 activation in NTB and TB
KPC mice, whereas < 2% of hepatocytes showed STAT3 activation in control mice (Fig.
3.7b, c). In contrast to STAT3 signaling, we did not detect activation of STAT1 signaling
in the liver of NTB or TB KPC mice (Fig. 3.8c). Orthotopic implantation of PDAC cells
into wild type mice also induced robust phosphorylation of STAT3 in hepatocytes (Fig.
3.8d-h), demonstrating that primary PDAC development drives activation of STAT3
signaling in hepatocytes.
We next hypothesized that activation of STAT3 signaling in hepatocytes may also
be required for the formation of a pro-metastatic niche in the liver. To test this hypothesis,
we first examined the liver of syngeneic control mice (Il-6+/+) and IL-6 knockout mice (Il6-/-) orthotopically injected with PBS or PDAC cells (Fig. 3.7d). Whereas genetic ablation
of host-derived Il-6 only modestly impacted STAT3 activation in the primary tumor111,
tumor-implanted Il-6-/- mice displayed a profound decrease in STAT3 activation in the liver,
particularly in hepatocytes (Fig. 3.7e and Fig. 3.9a). This loss in STAT3 activation was
accompanied by a significant decrease in the number of F4/80+ and Ly6G+ myeloid cells
as well as extracellular matrix deposition within the liver without alterations in the
morphology and density of liver sinusoids (Fig. 3.7e and Fig. 3.9a, b). The decreased
accumulation of myeloid cells in the liver of tumor-implanted Il-6-/- mice also correlated
with reduced expression of SAA (Fig. 3.7f) and other myeloid chemoattractants (Fig. 3.9c).
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Genetic ablation of host-derived Il-6, however, did not impact proliferation, vascular
density, or weight of the primary tumor (Fig. 3.9d, e), suggesting that the absence of a prometastatic niche in the liver of Il-6-/- mice is not attributable to impaired growth of the
primary tumor. Further corroborating the importance of IL-6 in establishing a prometastatic niche in the liver was the reduced susceptibility of the liver of Il-6-/- mice to
metastatic colonization and growth (Fig. 3.7g-i and Fig. 3.9f-i). Pharmacologic blockade
of IL-6 receptor (IL-6R) using anti-IL-6R antibodies similarly inhibited the formation of a
pro-metastatic niche and metastatic colonization in the liver (Fig. 3.10). Collectively, our
data demonstrate a role for IL-6 in directing liver metastasis.

Non-malignant cells are the predominant source of IL-6
IL-6 is a pro-inflammatory cytokine that promotes development and progression of
PDAC69,70,111,112. Some studies have shown that IL-6 expression is restricted to nonmalignant cells, including macrophages70 and fibroblasts113, but malignant cells have also
been identified as a source of IL-6114. To evaluate a role for non-malignant versus
malignant cells as the predominant source of IL-6, we orthotopically injected PBS or
PDAC cells into Il-6+/+ and Il-6-/- mice and determined the concentration of IL-6 present in
the pancreas or primary tumor, portal vein, and left ventricle of the heart (Fig. 3.11a). We
detected IL-6 only in tumor-implanted Il-6+/+ mice, with the highest concentration of IL-6
found in the primary tumor. Lower levels of IL-6 were detected in the portal vein, with
further decreased levels observed in the systemic circulation (Fig. 3.11b, c). These results
suggest that non-malignant cells are the major source of IL-6 that is detected both locally
and systemically during primary pancreatic tumor development.
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To identify non-malignant cells that produce IL-6, we examined for the presence
of Il-6 mRNA in the primary tumor and distant organs using RNA in situ hybridization.
While we did not detect Il-6 mRNA in the liver, lung, and malignant cells, some host cells
located adjacent to CK19-expressing PDAC cells in the primary tumor were found to
express IL-6 (Fig. 3.11d, e). Specifically, Il-6 mRNA was observed in alpha smooth muscle
actin (α-SMA)-expressing perivascular cells and stromal cells as well as CD31+
endothelial cells (Fig. 3.11f, g). We also detected IL-6 mRNA in the same cell types in
human primary tumors, whereas CK19-expressing malignant cells did not express IL-6
mRNA (Fig. 3.11h). These results indicate that multiple non-malignant cell types present
within the primary tumor are the source of IL-6.

STAT3 signaling in hepatocytes orchestrates the formation of a pro-metastatic niche
Based on the anatomic proximity of the pancreas to the liver, we next hypothesized
that IL-6 released by non-malignant cells in the pancreas acts as a direct mediator of
STAT3 signaling in hepatocytes. To evaluate this hypothesis, we established an in vitro
assay to determine the capacity of primary pancreatic tumor supernatant, which contains
secreted soluble factors present within tumor tissue, to activate STAT3 signaling in
cultured primary hepatocytes. We found that tumor supernatant obtained from wild type
mice orthotopically implanted with PDAC cells activated STAT3 signaling in
approximately 60% of hepatocytes, on a par with levels obtained with recombinant IL-6
(Fig. 3.12a). In addition, hepatocytes pre-incubated with anti-IL-6R antibodies prior to
stimulation with tumor supernatant showed reduced levels of STAT3 activation (Fig.
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3.12b), suggesting that IL-6 released by the primary tumor is a key mediator of STAT3
signaling in hepatocytes.
To better understand a role for STAT3 signaling in hepatocytes in directing liver
metastasis, we generated mice that lack Stat3 specifically in hepatocytes (Stat3flox/flox AlbCre). Deletion of Stat3 in hepatocytes did not affect liver sinusoid density or morphology
and did not alter the size, proliferation or vascular density of the primary tumor (Fig. 3.13ad). However, compared to syngeneic control mice (Stat3flox/flox), tumor-implanted
Stat3flox/flox Alb-Cre mice lacked key features of a pro-metastatic niche in the liver (Fig.
3.12c, d). The liver of Stat3flox/flox Alb-Cre mice was also less susceptible to metastatic
colonization compared to control mice (Fig. 3.13e-j). Collectively, these data demonstrate
that STAT3 signaling in hepatocytes is necessary for the formation of a pro-metastatic
niche in the liver.

Discussion
Here, we report several findings relevant to the understanding of processes that
govern metastatic spread of PDAC to the liver. First, primary PDAC development induces
robust activation of STAT3 signaling in hepatocytes. Second, activation of STAT3
signaling in hepatocytes is dependent on IL-6 that is released into the circulation by nonmalignant cells, including stromal cells and endothelial cells, that reside within the primary
pancreatic tumor. Third, hepatocyte activation engenders myeloid cell accumulation and
fibrosis within the liver, which together form a pro-metastatic niche that supports
metastatic seeding and growth. Finally, therapeutic blockade or genetic ablation of
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components of IL-6/STAT3 signaling in hepatocytes effectively inhibits the formation of
a pro-metastatic niche and prevents metastatic colonization of the liver.
Solid tumors, including PDAC, are often described to be in a perpetual state of
“wound healing” because of pervasive immune cell infiltration and fibrosis115. Intriguingly,
IL-6/STAT3 signaling in hepatocytes has been studied in the setting of liver fibrosis and
regeneration116. While these processes and the establishment of a pro-metastatic niche are
biologically distinct, parallels can be drawn in that both processes induce myeloid cell
accumulation and extracellular matrix remodeling within the liver. In models of liver injury,
IL-6/STAT3 signaling protects hepatocytes from apoptosis and promotes cellular
proliferation117-120. Activation of IL-6/STAT3 signaling is also important for recruiting
myeloid cells that attenuate inflammatory responses that may cause liver injury121-123. In
addition, deposition of extracellular matrix proteins that follows liver injury124,125 closely
resembles fibrosis that occurs early during primary PDAC development. Specifically, FN
deposition, which is a defining feature of a pro-metastatic niche in the liver, is critical for
survival of hepatocytes and tissue repair126-128. Our results indicate that pancreatic cancer
co-opts biological processes that are typically associated with liver injury and regeneration
to promote metastatic colonization of the liver.
Our studies also identify myeloid chemoattractants, including SAA and S100
proteins, that may be important effectors of IL-6/STAT3 signaling in hepatocytes. Future
studies will focus on identifying cellular targets of myeloid chemoattractants, as well as
further exploring a role for hepatic inflammation in directing the formation of a prometastatic niche in other types of cancers that frequently metastasize to the liver.
Furthermore, it will be important to understand if mechanisms described here can be
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extended to organs other than the liver that are frequently affected by metastatic disease.
Our data demonstrate a role for hepatocytes in directing organ-specific metastasis and
reveal therapeutic targets for pancreatic cancer.

Materials and methods
Animals
C57BL/6J (wild type), Il-6 knockout (Il-6-/-, B6.129S2-Il6tm1Kopf/J), Stat3flox/flox
(B6.129S1-Stat3tm1Xyfu/J), and Albumin-Cre+/+ (B6.Cg-Tg(Alb-cre)21Mgn/J) mice were
obtained from the Jackson Laboratory. Stat3flox/flox mice were bred to Albumin-Cre+/+ mice
to generate Stat3flox/+ Albumin-Cre+/- mice, which were backcrossed onto Stat3flox/flox mice
to generate Stat3flox/flox Albumin-Cre+/- mice. These mice were then bred to each other to
create Stat3flox/flox Albumin-Cre+/+ and Stat3flox/flox Albumin-Cre+/- mice (Stat3flox/flox Alb-Cre),
and Stat3flox/flox Albumin-Cre-/- mice (Stat3flox/flox). KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre
(KPC) mice and Trp53LSL-R172H/+;Pdx1-Cre (PC) mice were previously described44,104. All
transgenic mice were bred and maintained in the animal facility of the University of
Pennsylvania. Animal protocols were reviewed and approved by the Institute of Animal
Care and Use Committee of the University of Pennsylvania.

Cell lines
PDA.69 cell line was used for intrasplenic and orthotopic injection, and PDA.8572
cell line was used for intrasplenic, intraportal, and retro-orbital injections. These cell lines
were derived from PDAC tumors spontaneously arising in KPC mice as previously
described44,129. Cell lines were cultured in DMEM (Corning) supplemented with 10% fetal
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bovine serum (FBS, VWR), 83 µg/mL gentamicin (Thermo Fisher), and 1% GlutaMAX
(Thermo Fisher) at 37 °C, 5% CO2. Only cell lines that had been passaged less than 10
times were used for experiments, and trypan blue staining was used to ensure that cells
with > 95% viability were used for studies. Cell lines were tested routinely for Mycoplasma
contamination at the Cell Center Services Facility at the University of Pennsylvania.

Animal experiments
For orthotopic and intrasplenic injections of pancreatic tumor cells, mice were
anesthetized using continuous isoflurane, and their abdomen was sterilized. After
administering analgesic agents and assessing the depth of anesthesia, laparotomy (5-10 mm)
was performed over the left upper quadrant of the abdomen to expose the peritoneal cavity.
For orthotopic injection, the pancreas was exteriorized onto a sterile field, and sterile PBS
or pancreatic tumor cells (5 × 105 cells suspended in 50 µL of sterile PBS) were injected
into the tail of the pancreas via a 30-gauge needle (Covidien). Successful injection was
confirmed by the formation of a liquid bleb at the site of injection with minimal fluid
leakage. The pancreas was then gently placed back into the peritoneal cavity. For
intrasplenic injection, 150 µL of sterile PBS was drawn into a syringe then sterile PBS or
pancreatic tumor cells (5 × 105 cells suspended in 100 µL of sterile PBS) were gently drawn
into the same syringe in an upright position as previously described94. After exteriorizing
the spleen onto a sterile field, pancreatic tumor cells were injected into the spleen via a 30gauge needle. Successful injection was confirmed by whitening of the spleen and splenic
blood vessels with minimal leakage of content into the peritoneum. Splenectomy was then
performed by ligating splenic vessels with clips (Horizon) then cauterizing them to ensure
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that there was no hemorrhage. Afterwards, the remaining blood vessels were placed back
into the peritoneal cavity. For both procedures, the peritoneum was closed with a 5-0 PDS
II violet suture (Ethicon), and the skin was closed using the AutoClip system (Braintree
Scientific). Afterwards, mice were given buprenorphine subcutaneously at a dose of 0.050.1 mg/kg every 4-6 hours for 12 hours and then every 6-8 hours for 3 additional days.
For intraportal injection of pancreatic tumor cells and hydrodynamic injection of
expression vectors, mice were anesthetized using continuous isoflurane, and their abdomen
was sterilized. After administration of analgesic agents, median laparotomy (10 mm) was
performed, and the incision site was held open using an Agricola retractor (Roboz). After
exposure of the peritoneal cavity, the intestines were located and exteriorized onto a sterile
field surrounding the incision site to visualize the portal vein. Throughout the procedure,
the intestines were kept hydrated with sterile PBS that was pre-warmed at 37 ºC. For
intraportal injection, sterile PBS or pancreatic tumor cells (5 × 105 cells suspended in 100
µL of sterile PBS) were injected into the portal vein via a 30-gauge needle. Successful
injection was confirmed by partial blanching of the liver.
For administration of antibodies, the abdomen of mice was sterilized, and anti-CD4
antibodies (GK1.5, 0.2 mg), anti-CD8 antibodies (2.43, 0.2 mg), anti-IL-6R antibodies
(15A7, 0.2 mg), or rat isotype control antibodies (LTF-2, 0.2 mg) were suspended in 100
µL of sterile PBS. Antibodies were subsequently injected into the peritoneum via a 30gauge needle. All antibodies used in in vivo experiments were obtained from BioXCell. To
deplete F4/80+ myeloid cells, clodronate-encapsulated liposomes (Liposoma) were
administered via intraperitoneal injection according to manufacturer’s protocol. Detailed
information on antibodies and reagents used in experiments can be in found in Table 3.3.
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Microscopic analysis
For preparation of formalin-fixed paraffin-embedded (FFPE) sections, dissected
tissues were fixed in 10% formalin for 24 hours at room temperature, washed two times
with PBS, and then stored in 70% ethanol solution at 4 ºC until they were embedded in
paraffin and sectioned at 5 µm. For preparation of cryosections, dissected tissues were
embedded in Tissue-tek O.C.T. (Electron Microscopy Sciences) and frozen on dry ice.
Frozen tissues were stored at -80 ºC until they were sectioned at 7 µm.
Automated immunohistochemistry and immunofluorescence were performed on
FFPE sections using a Ventana Discovery Ultra automated slide staining system (Roche).
Reagents were obtained from Roche (Table 3.3) and used according to manufacturer’s
protocol. Images were acquired using a BX43 upright microscope (Olympus), an Aperio
CS2 scanner system (Leica), or an IX83 inverted multicolor fluorescent microscope
(Olympus). For manual multicolor immunofluorescence staining, O.C.T. liver cryosections
were briefly air dried and fixed with 3% formaldehyde at room temperature for 15 minutes.
For intracellular staining, sections were permeabilized with methanol at -20 ºC for 10
minutes immediately following formaldehyde fixation. Sections were then blocked with
10% normal goat serum in PBS containing 0.1% TWEEN 20 for 30 minutes. For
intracellular staining, 0.3% Triton X-100 was added to the blocking solution for
permeabilization of cellular and nuclear membranes. Sections were incubated with primary
antibodies (Supplementary Table 3) in the blocking solution for 1 hour at room temperature
or overnight at 4 ºC, followed by washing with PBS containing 0.1% TWEEN 20. Sections
were then incubated with secondary antibodies (Supplementary Table 3) in the blocking
solution for 1 hour at room temperature or overnight at 4 ºC. After washing, sections were
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stained with DAPI to visualize nuclei and subsequently with Sudan Black B in 70% ethanol
to reduce autofluorescence as previously described130. Immunofluorescence imaging was
performed on an IX83 inverted multicolor fluorescent microscope (Olympus). For
quantification of cells and extracellular matrix proteins, 5 random fields were acquired
from each biological sample.

Flow cytometry
Mice were euthanized, and the liver and lung were harvested after draining the
blood by severing the portal vein and inferior vena cava. The liver and lung were rinsed
thoroughly in PBS before mincing with micro dissecting scissors into small pieces (< 0.5
× 0.5 mm in size) at 4 °C in DMEM containing collagenase (1 mg/mL, Sigma-Aldrich),
DNase (150 U/mL, Roche), and Dispase (1 U/mL, Worthington). Tissues were then
incubated at 37 ºC for 30 minutes with intermittent agitation, filtered through a 70-µm
nylon strainer (Corning), and washed three times with DMEM. Cells were resuspended in
ACK lysing buffer (Life Technologies) at room temperature for 15 minutes to remove red
blood cells. After washing three times with DMEM, cells were counted and stained using
Aqua dead cell stain kit (Life Technologies) following manufacturer’s protocol. For
characterization of immune cell subsets, cells were washed three times with PBS
containing 0.2 mM EDTA with 2% FBS and stained with appropriate antibodies
(Supplementary Table 3). For quantification of PDAC-YFP cells, cells were not stained
with any antibodies. Lastly, cells were washed three times with PBS containing 0.2 mM
EDTA with 2% FBS and examined using a FACS Canto II (BD Biosciences). Collection
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and analysis of the peripheral blood was previously described129. FlowJo (FlowJo, LLC,
version 10.2) was used to analyze flow cytometric data and generate 2D t-SNE plots.

Detection of IL-6 and SAA
Mice that were orthotopically implanted with PDAC cells were euthanized, and
primary tumors were harvested and weighed. In addition, blood samples were collected
from the portal vein and left ventricle of the heart using a 27-gauge needle. Tumors were
rinsed thoroughly in PBS and minced with micro dissecting scissors into small pieces (<
0.5 × 0.5 mm in size) at 4 °C in serum-free DMEM at 1 mg of tissue per 1 µL of medium.
Tumor suspensions were then centrifuged at 12,470 × g at 4 °C for 15 minutes, and tumor
supernatant was collected and stored at -80 °C until analysis. Similar procedure was
performed to obtain pancreas supernatant from mice that were orthotopically injected with
PBS. To collect the serum, blood samples were allowed to clot at room temperature for 30
minutes. Samples were then centrifuged at 12,470 × g at 4 °C for 15 minutes, and the serum
was collected and stored at -80 °C until analysis. IL-6 levels in tumor/pancreas supernatant
and serum were assessed using cytometric bead array (BD Biosciences) following
manufacturer’s protocol. Samples were examined using a FACS Canto II (BD Biosciences),
and data were analyzed using FCAP Array (BD Biosciences, version 3.0). SAA levels in
mouse serum samples were measured using a commercially available enzyme-linked
immunosorbent assay kit (Thermo Fisher) following manufacturer’s protocol.
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RNA and quantitative real-time PCR
Mouse organs and cells were stored in TRIzol (Thermo Fisher) at -80 °C until
analysis. Samples were thawed on ice and allowed to equilibrate to room temperature prior
to isolating RNA using a RNeasy Mini kit (Qiagen) following manufacturer’s protocol.
cDNA synthesis was performed as previously described131. Primers for quantitative realtime PCR were designed using the Primer3 online program119, and sequences were
analyzed using the Nucleotide BLAST (NCBI) to minimize non-specific binding of
primers. Primers were synthesized by Integrated DNA Technologies, and their sequences
can be found in Table 3.4. Quantitative real-time PCR was performed as previously
described131. Gene expression was calculated relative to Actb (β-actin) using the delta-Ct
(∆Ct) formula, and fold change in gene expression was calculated relative to the average
gene expression of control groups using the delta delta Ct (∆∆Ct) formula. Genes with Ct
greater than or equal to 30 were considered not detected.

QuantSeq 3’ mRNA sequencing and data analysis
RNA was isolated from liver tissues as described above and submitted to the
Genomics Facility at the Wistar Institute. After assessing the quality of RNA using a 2100
Bioanalyzer (Agilent), samples were prepared using a QuantSeq 3’ mRNA-Seq library
prep kit FWD for Illumina (Lexogen) following manufacturer’s protocol and analyzed on
a NextSeq 500 sequencing system (Illumina). FASTQ files were uploaded to the
BaseSpace Suite (Illumina) and aligned using its RNA-Seq Alignment application (version
1.0.0), in which STAR was selected to align sequences with maximum mismatches set to
14 as recommended by Lexogen. Output files were analyzed using Cufflinks Assembly &
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DE application (version 2.1.0) in the BaseSpace Suite to determine differentially expressed
genes, which were used to generate an expression heatmap and a FPKM scatter plot. In
addition, these genes were analyzed using ClueGO (version 2.3.3)132 and CluePedia
(version 1.3.3)133, which are applications of Cytoscape software (version 3.5.1)134.
Functional group of biological processes were performed based on kappa score. Gene
Ontology data135,136 downloaded on January 23, 2018 were used for analysis. Gene set
enrichment analysis (version 3.0)137 was used to determine biological processes that were
differentially enriched in experimental groups.

In vitro studies
To isolate primary hepatocytes for in vitro studies, mice were anesthetized using
continuous isoflurane, and their abdomen was sterilized. After administering analgesic
agents and assessing the depth of anesthesia, laparotomy (10-15 mm) was performed along
the midline of the abdomen to expose the peritoneal cavity. The intestines were then located
and exteriorized to visualize the inferior vena cava and portal vein. The inferior vena cava
was cannulated via a 24 gauge Insyte Autoguard cathether (BD), and the liver was perfused
using 50 mL of liver perfusion medium (Thermo Fisher) at the flow rate of 8-9 mL/min
using a peristaltic pump. At the start of perfusion, the portal vein was severed to drain the
blood from the liver. Successful perfusion was confirmed by blanching of the liver, which
was subsequently perfused using 50 mL of liver digest medium (Thermo Fisher) at the
same flow rate. Both liver perfusion medium and liver digest medium were pre-warmed at
42 °C in a water bath. After perfusion, the liver was carefully transferred to a petri dish
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containing William’s E medium (Sigma) supplemented with 10% FBS, 83 µg/mL
gentamicin, and 1% GlutaMAX.
To dissociate hepatocytes from the liver, cell scrappers were used to create small
cuts (5 mm) on the surface of the liver, and the tissue was gently shaken. Dissociated cells
were then filtered through a 100-µm nylon strainer (Corning) and centrifuged at 50 × g at
4 °C for 5 minutes. After discarding the supernatant, cells were resuspended in a solution
consisting of isotonic Percoll (Sigma) and supplemented William’s E medium (2:3 ratio).
Cells were then centrifuged at 50 × g at 4 °C for 10 minutes to obtain a pellet enriched in
hepatocytes. After discarding the supernatant, hepatocytes were resuspended in
supplemented William’s E medium. Cell viability and number were determined using
trypan blue staining, and 5 × 104 hepatocytes were seeded on each well of a 48-well plate
pre-coated with collagen. Hepatocytes were incubated in supplemented William’s E
medium for 4 hours at 37 °C, 5% CO2 to allow attachment to the plate. Medium was then
switched to HepatoZYME-SFM (Thermo Fisher) supplemented with 83 µg/mL gentamicin
and 1% GlutaMAX. Medium was replenished every 24 hours for the next 48 to 72 hours.
For hepatocyte activation assays, hepatocytes were incubated in supplemented
HepatoZYME-SFM mixed with (i) serum-free DMEM, (ii) primary pancreatic tumor
supernatant, or (iii) serum-free DMEM containing 250 ng/mL of IL-6 (Peprotech) for 30
minutes at 37 °C, 5% CO2. All mixtures were made in a 1:1 ratio, and each condition was
run in triplicates. For in vitro IL-6R blockade experiment, hepatocytes were pre-incubated
with 5 µg/mL of anti-IL-6R antibodies for 2 hours prior to stimulating them with tumor
supernatant. After stimulation, medium was carefully removed, and formaldehyde and
methanol were used to fix and permeabilize hepatocytes, respectively, as described above.
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Hepatocytes were then stained for pSTAT3 (Supplementary Table 3), and their nuclei
stained with DAPI. Immunofluorescence imaging was performed on an IX83 inverted
multicolor fluorescent microscope (Olympus).

Statistical analysis
Statistical significance was calculated using Prism (GraphPad Software, version 7).
Multiple comparisons testing was performed using one-way ANOVA with Dunnett’s test.
Paired and unpaired group comparisons testing was carried out using Wilcoxon matchedpairs signed rank test and Mann-Whitney test, respectively. Comparison of Kaplan-Meier
overall survival curves was performed using log-rank (Mantel-Cox) test. P values less than
0.05 were treated as significant. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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Figures and figure legends

Figure 3.1 | Primary PDAC development induces a pro-metastatic niche in the liver.
a, Representative images and quantification of myeloid cells, FN, and COL1 in the liver of
control mice (n = 4-9), NTB KPC mice (n = 4-9), and TB KPC mice (n = 4-7). Arrows
indicate Ly6G+ cells. Scale bars, 50 µm. Data pooled from two experiments. b,
Representative images and flow cytometric analysis. Control mice (n = 14) and NTB KPC
mice (n = 10) were intrasplenically injected with PDAC-YFP cells (PDA.8572), and the
liver was harvested after 10 days. Scale bars,1 cm. c, Quantification of PDAC-YFP cells.
Data pooled from three experiments (b, c). d, Heat map showing differentially expressed
genes in the liver of control mice versus NTB KPC mice (n = 5 for both groups). e, Enriched
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biological processes in the liver of NTB KPC mice. f, Scatter plot of transcriptome data.
Myeloid chemoattractants are indicated. FPKM, fragments per kilobase of exon per million
mapped fragments. Data representative of one experiment (d-f). *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001 by one-way ANOVA or Mann-Whitney test. Data
represented as mean ± s.d.
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Figure 3.2 | Primary PDAC development induces myeloid cell accumulation and
fibrosis within the liver. a, Gating strategy for identification of F4/80+, Ly6G+, CD3+, and
CD19+ cells. Representative images from flow cytometric analysis of cells isolated from
the liver of a TB KPC mouse are shown. b, Quantification of immune cells in the liver of
control mice (n = 4), NTB KPC mice (n = 4), and TB KPC mice (n = 5-13) by flow
cytometry. Data pooled from four experiments. c, Study design. PDA.69 was used for
injection. d, Quantification of immune cells in the liver by flow cytometry (n = 5 for both
groups). e, t-SNE 2D plots of immune cells analyzed in d. f, Quantification of myeloid
cells (n = 7 for PBS and n = 6 for PDAC). g, Quantification of FN and COL1 (n = 6 for
both groups). Data representative of at least two independent experiments (c-g). *P < 0.05,
**P < 0.01, ***P < 0.001 by Mann-Whitney test. NS, not significant. Data represented as
box plots (center line, median; box limits, upper and lower quartiles; whiskers, max and
min values), except f and g, which are represented as mean ± s.d.

61

Figure 3.3 | F4/80+ myeloid cells are not required for deposition of extracellular
matrix proteins within the liver. a, Study design (n = 4 for mice orthotopically injected
with PBS; n = 4 and 3 for mice orthotopically injected with PDAC cells (PDA.69) and then
intraperitoneally injected with PBS and clodronate-encapsulated liposomes (CEL),
respectively, on days 1, 8, 11, and 14). b, Representative images of F4/80+ myeloid cells
in the liver. Scale bars, 50 µm. c, Quantification of F4/80+ myeloid cells in the liver. d,
Quantification of COL1 and FN in the liver. Data representative of one experiment (a-d).
**P < 0.01, ****P < 0.0001 by one-way ANOVA. NS, not significant. Data represented
as mean ± s.d.

62

Figure 3.4 | The liver of KPC mice is more susceptible to metastatic colonization
compared to control mice. a, Study design (n = 14 and 10 for control mice and NTB KPC
mice intrasplenically injected with PDAC-YFP cells (PDA.8572), respectively). b, c,
Representative images of the liver showing metastatic lesions (yellow, stained with CK19)
and Ki-67 (purple). Scale bars, 4 mm (b) and 200 µm (c). d, Quantification of lesions (left)
and Ki-67+ tumor cells (right). Data pooled from three experiments (a-d). e, Study design
(n = 9 and 13 for control mice intrasplenically injected with PBS and PDAC cells (PDA.69),
respectively; n = 6 and 13 for NTB KPC mice intrasplenically injected with PBS and PDAC
cells (PDA.69), respectively). f, Representative images of the liver (top) and metastatic
lesions in the liver (red, stained with Pdx1). Scale bars, 1 cm (top) and 50 µm (bottom). g,
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Liver weights. h, mRNA levels of Pdx1 in the liver relative to Gapdh. Data pooled from
five experiments (e-h). i, Study design (n = 4 for both groups of mice injected with PBS
and PDAC cells (PDA.69)). Both groups of mice were injected with PDAC-YFP cells
(PDA.8572) on day 10. j, Representative images and flow cytometric analysis. Scale bars,
1 cm. k, Quantification of PDAC-YFP cells. l, m, Representative images of the liver
showing metastatic lesions (yellow, stained with CK19) and Ki-67 (purple). Scale bars, 4
mm (l) and 200 µm (m). Data representative of at least three independent experiments (im). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by Mann-Whitney test or oneway ANOVA. NS, not significant. Data represented as mean ± s.d.
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Figure 3.5 | Metastatic colonization of the liver is not influenced by T cells. a, Study
design (n = 5 for both groups of mice injected with PBS and PDAC cells (PDA.69)). b,
Gating strategy for identification of T cell subsets. Representative images from flow
cytometric analysis of cells isolated from the liver of a wild type mouse are shown. EM,
effector memory. c, Quantification of CD4+ T cell subsets in the liver. d, Quantification of
CD8+ T cells in the liver. Data representative of two independent experiments (a-d). e,
Study design (n = 4 for both groups of mice injected with PBS and PDAC cells (PDA.69)).
Both groups of mice were injected with PDAC-YFP cells (PDA.8572) on day 10. f,
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Representative flow cytometric analysis of the peripheral blood and quantification of CD4+
and CD8+ T cells. g, Representative images and flow cytometric analysis of the liver. Scale
bars, 1 cm. h, Quantification of PDAC-YFP cells. i, Representative images of the liver
showing metastatic lesions (yellow, stained with CK19) and Ki-67 (purple). Scale bars,
200 µm. j, Quantification of lesions (left) and Ki-67+ tumor cells (right). k, Representative
images of the liver showing metastatic lesions (yellow, stained with CK19), CD4+ cells
(purple), and CD8+ cells (brown). Scale bars, 50 µm. l, Quantification of CD4+ cells (left)
and CD8+ cells (right). Data representative of one experiment (e-l). *P < 0.05 by MannWhitney test. NS, not significant. Data represented as mean ± s.d.
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Figure 3.6 | Primary PDAC development induces expression of myeloid
chemoattractants in the liver. a, Study design (n = 5 for control mice and NTB KPC
mice). b, FPKM values of chemoattractant genes in the liver of control mice and NTB KPC
mice. c, mRNA levels of chemoattractant genes in the liver of control mice (n = 10) and
NTB KPC mice (n = 9). Data representative of one experiment (a-c). *P < 0.05, **P <
0.01, ***P < 0.001 by Mann-Whitney test. NS, not significant. Data represented as box
plots (center line, median; box limits, upper and lower quartiles; whiskers, max and min
values).

67

Figure 3.7 | IL-6 is necessary for the establishment of a pro-metastatic niche in the
liver. a, Enrichment of IL-6/JAK/STAT3 signaling genes in the liver of NTB KPC mice
compared to control mice (n = 5 for both groups). FDR, false discovery rate; NES,
normalized enrichment score. Data representative of one experiment. b, Representative
images of hepatocytes (red, stained with albumin) and pSTAT3 (green) in control mice (n
= 4), NTB KPC mice (n = 5), and TB KPC mice (n = 5). Scale bars, 50 µm. c, Percentage
of hepatocytes that are pSTAT3+. Data pooled from two experiments (b, c). d, Study design
(n = 5 and 6 for Il-6+/+ mice injected with PBS and PDAC cells (PDA.69), respectively; n
= 4 and 5 for Il-6-/- mice injected with PBS and PDAC cells (PDA.69), respectively). e,
Quantification of pSTAT3+ cells, myeloid cells, and FN. f, mRNA levels of Saa. g, Study
design (n = 4 and 5 for Il-6+/+ mice injected with PBS and PDAC cells (PDA.69),
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respectively; n = 4 for Il-6-/- mice injected with PBS and PDAC cells (PDA.69)). All groups
of mice were injected with PDAC-YFP cells (PDA.8572) on day 10. h, Representative
images and flow cytometric analysis. Scale bars, 1 cm. i, Quantification of PDAC-YFP
cells. Data representative of two independent experiments (d-i). *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001 by one-way ANOVA or Mann-Whitney test. Data
represented as mean ± s.d.
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Figure 3.8 | Primary PDAC development activates STAT3 signaling in myeloid cells
and hepatocytes in the liver. a, Representative images of F4/80+ myeloid cells (red) and
pSTAT3 (green) in the liver of control mice (n = 9), NTB KPC mice (n = 8), and TB KPC
mice (n = 5). b, Percentage of F4/80+ myeloid cells that are pSTAT3+. c, Representative
images of F4/80+ myeloid cells (red) and pSTAT1 (green) in the liver of control mice (n =
9), NTB KPC mice (n = 8), and TB KPC mice (n = 5). Data pooled from two experiments
(a-c). d, Study design (n = 7 and 6 for wild type mice injected with PBS and PDAC cells
(PDA.69), respectively). e, Representative images of F4/80+ cells (red) and pSTAT3
(green). f, Percentage of F4/80+ cells that are pSTAT3+. g, Representative images of
hepatocytes (red, stained with albumin) and pSTAT3 (green). h, Percentage of hepatocytes
that are pSTAT3+. Scale bars, 50 µm. Data representative of two independent experiments
(d-h). **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA or Mann-Whitney
test. Data represented as mean ± s.d.

70

Figure 3.9 | IL-6 promotes the formation of a pro-metastatic niche in the liver. a,
Representative images of pSTAT3+ cells, myeloid cells, and FN. Il-6+/+ and Il-6-/- mice
were orthotopically injected with PBS (n = 5 for Il-6+/+; n = 4 for Il-6-/-) or PDAC cells
(PDA.69) (n = 6 for Il-6+/+; n = 5 for Il-6-/-), and the liver and pancreas/primary tumor were
harvested after 20 days. Arrows indicate Ly6G+ cells. b, Representative images of
sinusoids (brown, stained with CD31) in the liver. c, mRNA levels of Lcn2, S100a8,
S100a9, Ccl6, Cxcl1, and Fn1 in the liver. Data representative of two independent
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experiments (a-c). d, Representative images of the pancreas and primary tumor stained
with CD31 (brown), CK19 (yellow) and Ki-67 (purple). e, Quantification of the weight of
pancreas/primary tumor (left), number of Ki-67+ tumor cells (middle), and vascular area
(right). Data representative of one experiment (d, e). f, Study design (n = 5 for all groups
of mice injected with PBS and PDAC cells (PDA.69)). All groups of mice were injected
with PDAC-YFP cells (PDA.8572) on day 10. g, h, Representative images of the liver
showing metastatic lesions (yellow, stained with CK19) and Ki-67 (purple). Scale bars, 4
mm (g) and 200 µm (h). i, Quantification of lesions (top) and Ki-67+ tumor cells (bottom).
Data representative of one experiment (f-i). Scale bars, 50 µm unless indicated otherwise.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA. NS, not
significant. Data represented as mean ± s.d.
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Figure 3.10 | Blockade of IL-6R inhibits the establishment of a pro-metastatic niche
in the liver. a, Study design (n = 4 and 5 for mice injected with PBS and treated with
isotype control and anti-IL-6R antibodies, respectively; n = 7 and 8 for mice injected with
PDAC cells (PDA.69) and treated with isotype control and anti-IL-6R antibodies,
respectively). b, Representative images and quantification of pSTAT3+ cells, myeloid cells,
and FN. Arrows indicate Ly6G+ cells. Scale bars, 50 µm. c, mRNA levels of Saa. d, Study
design (n = 7 and 8 for mice injected with PBS and treated with isotype control and antiIL-6R antibodies, respectively; n = 7 for mice injected with PDAC cells (PDA.69) and
treated with isotype control and anti-IL-6R antibodies). All groups of mice were injected
with PDAC-YFP cells (PDA.8572) on day 10. e, Representative images and flow
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cytometric analysis. Scale bars, 1 cm. f, Quantification of PDAC-YFP cells. Data
representative of two independent experiments (a-f). **P < 0.01, ***P < 0.001, ****P <
0.0001 by one-way ANOVA. Data represented as mean ± s.d.
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Figure 3.11 | Non-malignant cells are the predominant source of IL-6. a, Study design
(n = 5 and 6 for Il-6+/+ mice injected with PBS and PDAC cells (PDA.69), respectively; n
= 4 and 5 for Il-6-/- mice injected with PBS and PDAC cells (PDA.69), respectively). SN,
supernatant. b, Concentration of IL-6 in pancreas supernatant and serum collected from
indicated sites in Il-6+/+ mice injected with PBS or PDAC cells. c, Concentration of IL-6
in pancreatic tumor supernatant and serum collected from indicated sites in Il-6-/- mice
injected with PBS or PDAC cells. Solid lines indicate data points from individual mice,
and dashed lines indicate the lower limit of detection (b, c). Data representative of two
independent experiments (a-c). d, Representative images of CK19 (green) and Il-6 (red) in
the pancreas and primary tumor. e, Representative images of Il-6 (red) in the liver and lung
of Il-6+/+ mice injected with PDAC cells. f, Study design (n = 4 for Il-6+/+ mice injected
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with PDAC cells (PDA.69) and n = 5 for human samples). g, Representative images of α
-SMA (green), CD31 (green), CK19 (green), and Il-6 (red) in perivascular cells (top),
stromal cells (bottom, left), endothelial cells (bottom, middle) and malignant cells (bottom,
right) present within the mouse primary tumor. h, Representative images of α-SMA
(yellow), CD31 (yellow), CK19 (yellow), and IL-6 (brown) in perivascular cells (top, left),
stromal cells (top, right), endothelial cells (bottom, left) and malignant cells (bottom, right)
present within the human primary tumor. Data representative of one experiment (f-h).
Scale bars, 50 µm. *P < 0.05 by Wilcoxon test. NS, not significant. BV, blood vessel.
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Figure 3.12 | STAT3 signaling in hepatocytes orchestrates the formation of a prometastatic niche in the liver. a, b, Representative images and quantification of pSTAT3+
hepatocytes (red) (n = 3 technical replicates per condition). Arrows indicate pSTAT3+
hepatocytes. SN, pancreatic tumor supernatant. Scale bars, 50 µm. c, Study design (n = 4
for Stat3flox/flox mice injected with PBS and PDAC cells (PDA.69); n = 8 and 7 for
Stat3flox/flox Alb-Cre mice injected with PBS and PDAC cells (PDA.69), respectively). d,
Quantification of pSTAT3+ cells, myeloid cells, and FN. Data representative of two
independent experiments (a-d). ***P < 0.001, ****P < 0.0001 by one-way ANOVA. Data
represented as mean ± s.d.
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Figure 3.13 | STAT3 signaling in hepatocytes promotes the formation of a prometastatic niche in the liver. a, Study design (n = 4 for Stat3flox/flox mice injected with PBS
and PDAC cells (PDA.69); n = 8 and 7 for Stat3flox/flox Alb-Cre mice injected with PBS and
PDAC cells (PDA.69), respectively). b, Representative images of sinusoids (brown,
stained with CD31) in the liver. c, Representative images of the pancreas and primary
tumor stained with CD31 (brown), CK19 (yellow) and Ki-67 (purple). d, Quantification of
the weight of pancreas/primary tumor (left), number of Ki-67+ tumor cells (middle), and
vascular area (right). e, Study design (n = 5 for all groups of mice injected with PBS and
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PDAC cells (PDA.69)). All groups of mice were injected with PDAC-YFP cells
(PDA.8572) on day 10. f, Representative flow cytometric analysis. g, Quantification of
PDAC-YFP cells. h, i, Representative images of the liver showing metastatic lesions
(yellow, stained with CK19) and Ki-67 (purple). Scale bars, 4 mm (h) and 200 µm (i). j,
Quantification of lesions (top) and Ki-67+ tumor cells (bottom). Data representative of one
experiment (a-j). Scale bars, 50 µm unless indicated otherwise. *P < 0.05, ***P < 0.001,
****P < 0.0001 by one-way ANOVA. NS, not significant. Data represented as mean ± s.d.
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Table 3.1 | List of differentially expressed genes. Data obtained from QuantSeq 3' mRNA
sequencing on RNA isolated from the liver of control mice (n = 5) and NTB KPC mice (n
= 5) were analyzed using Cufflinks Assembly & DE application to determine differentially
expressed genes.
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Table 3.2 | Gene set enrichment analysis. Gene sets enriched in the liver of NTB KPC
mice (n = 5) compared to control mice (n = 5). Only gene sets with FDR q < 0.25 are shown.
Nom., nominal; FDR, false discovery rate; NES, normalized enrichment score. Data
representative of one experiment.
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Table 3.3 | Antibodies, probes, and reagents used in experiments. AP, alkaline
phosphatase; DAB, 3,3’-diaminobenzidine; FAM, fluorescein amidite; FCM, flow
cytometry;

HRP,

horseradish

peroxidase;

IF,

immunofluorescence;

IHC,

immunohistochemistry; ISH, in situ hybridization; NP, nitropyrazole. N/A, not applicable.
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Table 3.4 | Primer sequences.
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CHAPTER 4: Serum Amyloid A1 and 2 Direct the Formation of a ProMetastatic Niche in the Liver.
The contents of this chapter have been published:
Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H.,
Delman, D., Graham, K., Gladney, W. L., Hua, X., Black, T. A., Chien, A. L.,
Majmundar, K. S., Thompson, J. C., Yee, S. S., O’Hara, M. H., Aggarwal, C., Xin,
D., Shaked, A., Gao, M., Liu, D., Borad, M. J., Ramanathan, R. K., Carpenter, E.
L., Ji, A., de Beer, M. C., de Beer, F. C., Webb, N. R. & Beatty, G. L. Hepatocytes
direct the formation of a pro-metastatic niche in the liver. Nature (2019).

Abstract
Serum amyloid A1 and A2 (SAA) are acute phase reactants that are produced in
inflammatory conditions, including infection and cancer138. We have previously shown in
Chapter 3 that increased expression of SAA in the liver is associated with the formation of
a pro-metastatic niche in the liver. However, the precise role for SAA in regulating this
process is not known. Here, we show that SAA engenders the accumulation of myeloid
cells and deposition of extracellular matrix proteins within the liver, the hallmarks of a prometastatic niche. During pancreatic ductal adenocarcinoma (PDAC) and colorectal
carcinoma (CRC) development in mice, hepatocytes produce SAA following activation of
Signal Transducer and Activator of Transcription 3 (STAT3) signaling. Overexpression of
SAA by hepatocytes also occurs in PDAC and CRC patients with liver metastases, and
many patients with locally advanced and metastatic disease display elevated levels of
circulating SAA, which are correlated with worse overall survival. Genetic ablation of
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SAA inhibits the formation of a pro-metastatic niche and metastatic colonization of the
liver. Together, our results identify hepatocyte-derived SAA as a key mediator of the
establishment of a pro-metastatic niche in the liver.

Introduction
The acute phase response is an early defense response that is mounted by the innate
immune system in the setting of trauma and infection139. During this process, the body
synthesizes acute phase reactants that facilitate elimination of pathogens and promote
tissue repair to restore homeostasis. SAA is a major acute phase reactant whose circulating
levels increase as much as 1,000-fold during acute inflammation140. Evolutionarily
conserved in mammals141,142 and other vertebrate species143, SAA is believed to be an
archetypal acute phase reactant critical for host defense from environmental insults.
Immunological functions exerted by SAA include induction of myeloid cell migration and
production of proinflammatory cytokines by immune cells144.
In addition to key roles that SAA has in acute inflammation, SAA may participate
in the pathogenesis and progression of chronic inflammatory conditions, including
autoimmune diseases and malignancy138. In particular, development of PDAC in patients
is associated with elevated levels of circulating SAA, and based on this finding, SAA has
recently been proposed to be a diagnostic biomarker for PDAC145. We have also
demonstrated in Chapter 3 that the formation of a pro-metastatic niche in the liver is
associated with elevated expression levels of SAA. However, the precise role for SAA in
regulating metastatic spread of tumor cells to the liver is unknown. Identification of
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processes that regulate production of SAA as well as mechanisms by which SAA promotes
liver metastasis may provide important insights into the pathogenesis of metastatic disease.

Results
STAT3 signaling in hepatocytes regulates production of SAA in the setting of PDAC
Primary PDAC development induces a pro-metastatic niche in the liver. This
process is dependent on activation of STAT3 signaling in hepatocytes and is accompanied
by production of SAA by hepatocytes (Fig. 4.1a, b). Previous studies have shown that
production of SAA by hepatocytes is regulated by STAT3 signaling in the setting of
infection and liver injury119,121,123. Hence, we hypothesized that STAT3 signaling in
hepatocytes may also be required for production of SAA in the setting of primary PDAC
development. To test this, we generated mice that lack Stat3 specifically in hepatocytes
(Stat3flox/flox Alb-Cre). Compared to syngeneic control mice (Stat3flox/flox), Stat3flox/flox AlbCre mice that were orthotopically implanted with PDAC cells showed minimal levels of
SAA in the liver (Fig. 4.1c-e) and systemic circulation (Fig. 4.1f). In addition to its
expression in hepatocytes, we detected Saa mRNA in colonic intestinal cells as previously
reported146, although these cells did not show significant changes in Saa mRNA levels in
response to primary tumor development (Fig. 4.1g). Together, these data demonstrate that
STAT3 signaling in hepatocytes is necessary for the formation of a pro-metastatic niche in
the liver and for production of SAA.
Consistent with elevated levels of circulating SAA that were observed in control
mice implanted with PDAC cells, PDAC patients with locally advanced disease or with
liver metastases displayed significantly higher levels of circulating SAA compared to

90

normal donors (Fig. 4.2a). Increased and diffuse expression of SAA and pSTAT3 by
hepatocytes was also observed in 5 out of 7 (71%) patients with liver metastases (Fig. 4.2b
and Fig. 4.3a), further corroborating that hepatocytes are activated to produce these acute
phase reactants in the setting of PDAC. Notably, high levels of circulating SAA correlated
with worse outcomes in PDAC patients with liver metastases (Fig. 4.3b). Elevated levels
of circulating SAA were also observed in non-small cell lung carcinoma (NSCLC) patients
with liver metastases, and increased expression of SAA by hepatocytes was detected in the
liver of CRC patients with liver metastases (Fig. 4.4a, b). Together, these findings
suggested a role for SAA in directing liver metastasis.

SAA is a critical determinant of liver metastasis
To further examine a role for SAA in regulating liver metastasis, we performed
tumor implantation studies using Saa knockout mice (Saa-/-) (Fig. 4.2c). Compared to
tumor-implanted syngeneic control mice (Saa+/+), Saa-/- mice that were implanted with
PDAC cells or MC-38 CRC cells failed to show features of a pro-metastatic niche in the
liver (Fig. 4.2d, e, Fig. 4.4c, d, and Fig. 4.5a, b). Saa-/- mice also displayed reduced levels
of myeloid chemoattractants within the liver, including Ccl6, Lcn2, S100a8, and S100a9.
(Fig. 4.5c). Moreover, Saa-/- mice implanted with an orthotopic tumor showed decreased
susceptibility to metastatic colonization in the liver compared to control mice. Genetic
ablation of Saa had no impact on primary tumor growth (Fig. 4.2f-h and Fig. 4.5d-i),
suggesting that reduced metastatic colonization observed in Saa-/- mice was not attributable
to impaired growth of the primary tumor.
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Recent studies that have demonstrated the capacity of SAA to stimulate production
of chemokines in non-cancer models147,148. Based on these studies, we hypothesized that
STAT3 activation and production of SAA by hepatocytes may be a general mechanism
that directs liver inflammation and fibrosis. To test this hypothesis, we induced persistent
overexpression of interleukin 6 (IL-6) to activate STAT3 signaling in the liver of control
mice, Il-6-/- mice, and Saa-/- mice using hydrodynamic delivery of IL-6 expression
vectors149 (Fig. 4.6a, b). Overexpression of IL-6 in control mice and Il-6-/- mice induced
robust activation of STAT3 signaling in the liver accompanied by the accumulation of
myeloid cells as well as fibrosis (Fig. 4.6c). However, Saa-/- mice injected with IL-6
expression failed to show an increase in myeloid cell accumulation and fibrosis within the
liver (Fig. 4.6c), suggesting that IL-6 is sufficient for orchestrating elements of a prometastatic niche in the liver and that this process is dependent on SAA. FN deposition and
myeloid cell recruitment in the setting of liver injury was also dependent on SAA (Fig. 4.7).
Together, our data show that IL-6/STAT3/SAA signaling in hepatocytes directs liver
inflammation and fibrosis.
We next determined whether the formation of a pro-metastatic niche in the liver is
dependent on the anatomic proximity of the pancreas to the liver. To do so, we performed
parabiotic joining of tumor-implanted mice (CD45.2, left) and control mice (CD45.1, right)
and examined for key features of a pro-metastatic niche in the liver (Fig. 4.9a-c). Both
parabiotic partners displayed myeloid cell accumulation and fibrosis in the liver (Fig. 4.9d),
suggesting that the formation of this niche is not dependent on the anatomic distance
between the pancreas and liver. Intriguingly, Saa mRNA and IL-6 levels were significantly
elevated only in tumor-implanted CD45.2 mice (Fig. 4.9e-g). However, elevated levels of
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circulating SAA were detected in both parabiotic partners, consistent with their shared
circulation (Fig. 4.9h). Collectively, these results indicate that PDAC development induces
local liver production of SAA, which then initiates a systemic effect to promote the
formation of a pro-metastatic niche in the liver.

SAA regulates the formation of a pro-metastatic niche independently of TIMP1 and MIF
Tissue inhibitor of metalloproteinases 1 (TIMP1) has recently been implicated in
promoting liver metastasis in PDAC18,19. In this model, malignant cells have been proposed
to secrete TIMP1, which then activates hepatic stellate cells and promotes the formation of
a pro-metastatic niche via a CD63/SDF1/CXCR4 mechanism. Consistent with previous
studies, we detected TIMP1 within the primary tumor (Fig. 4.8a, b). However, primary
tumor development did not alter expression levels of TIMP1 and other downstream
mediators within the liver (Fig. 4.8c, d). In addition, genetic ablation of components of IL6/STAT3/SAA signaling did not impact levels of TIMP1 within the primary tumor and
systemic circulation (Fig. 4.8e-p), suggesting that TIMP1 is not a downstream effector of
IL-6/STAT3/SAA signaling.
Macrophage migration inhibitory factor (MIF) is another molecule that has been
proposed to regulate the formation of a pro-metastatic niche in the liver in the setting of
PDAC14,15. Here, malignant cells are believed to secrete into the circulation MIF-positive
exosomes, which then stimulate liver-resident macrophages to deposit FN and recruit
myeloid cells into the liver in a TGF-β-dependent manner. As expected, we found that Mif
mRNA levels were elevated in PDAC tumors compared to normal pancreata (Fig. 4.8e-p).
However, Mif mRNA levels were not altered in mice that lack components of IL-
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6/STAT3/SAA signaling compared to control mice (Fig. 4.8e-p). Taken together, these
findings suggest IL-6/STAT3/SAA signaling in hepatocytes regulates the formation of a
pro-metastatic niche in the liver independently of TIMP1 and MIF.

The formation of a pro-metastatic niche in the lung is not dependent on SAA
Given that hepatocyte-derived SAA can enter the systemic circulation, we also
examined a role for SAA in establishing a pro-metastatic niche in the lung, which is another
common site of metastatic disease. PDAC development in KPC mice induced Ly6G+
myeloid cell accumulation and deposition of FN within the lung, yet the number of F4/80+
myeloid cells remained unchanged (Fig. 4.10a, b). Orthotopic implantation of PDAC cells
into control mice recapitulated these alterations in the lung, but genetic ablation of
components of IL-6/STAT3/SAA signaling did not affect the formation of a pro-metastatic
niche or metastatic colonization in the lung (Fig. 4.10c-j). Our findings suggest that
induction of a pro-metastatic niche by SAA is specific to the liver.

Discussion
Metastatic tropism of cancer was first described by Stephen Paget in 1889150, but
our understanding of mechanisms that govern this process remain incomplete. Here, we
provide novel insight into the mechanisms that direct metastatic spread of PDAC to the
liver. While recent works have suggested a role for tumor-intrinsic factors in driving
metastatic spread of PDAC14,15,18,19,151-153, we provide, to our knowledge, the first evidence
that inflammatory responses mounted by hepatocytes are critical to liver metastasis.
Mechanistically, hepatocytes orchestrate this process through activation of IL-6/STAT3
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signaling and the subsequent production of SAA, which alters the immune and fibrotic
microenvironment of the liver to establish a pro-metastatic niche (Fig. 4.11). Given that
SAA induces myeloid cell recruitment and fibrosis not only in tumor models but also in
the setting of liver injury, our data suggest that IL-6/STAT3/SAA signaling is a general
mechanism by which hepatocytes regulate inflammatory and fibrotic responses in the liver.
Given that SAA released by hepatocytes is detectable in the systemic circulation,
expression levels of SAA in patients can be readily assessed via the peripheral blood. Our
future studies will focus on evaluating the utility of SAA as a prognostic as well as
diagnostic marker of cancer metastasis. Intriguingly, despite the systemic release of SAA,
we find that SAA-mediated formation of a pro-metastatic niche is specific to the liver. This
finding suggests that cellular targets of SAA are likely liver-resident cells that have the
capacity to either directly or indirectly recruit myeloid cells and deposit extracellular
matrix proteins. One promising target of SAA is hepatic stellate cells, which have recently
been shown to produce chemokines and promote fibrogenesis in a SAA-dependent
manner148. In addition, liver-specific effect of SAA carries an important therapeutic
implication that effective inhibition of metastasis will likely require a therapeutic approach
that simultaneously targets multiple mechanisms governing organ-specific metastasis (e.g.,
liver versus lung). The current study highlights a role for hepatocytes in directing the
formation of a pro-metastatic niche in the liver and provides a framework for future
mechanistic studies by defining SAA as a key mediator of liver metastasis.
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Materials and methods
Animals
CD45.2 (wild type, C57BL/6J) and CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) were
obtained from the Jackson Laboratory. Il-6-/-, Stat3floxflox, and Stat3flox/flox Alb-Cre mice were
previously described in Chapter 3. Saa1 and Saa2 double knockout (Saa-/-) mice were
previously described154 and provided by the University of Kentucky College of Medicine.
Saa-/- mice used for experiments had been bred to obtain a 99.9% C57BL/6 background
using the Jackson Laboratory Speed Congenic Service154. All transgenic mice were bred
and maintained in the animal facility of the University of Pennsylvania. Animal protocols
were reviewed and approved by the Institute of Animal Care and Use Committee of the
University of Pennsylvania.

Clinical samples
All patient samples were obtained after written informed consent. Studies were
conducted in accordance with the 1996 Declaration of Helsinki and approved by
institutional review boards of the University of Pennsylvania and the Mayo Clinic. To
obtain the plasma from normal donors, PDAC patients, and NSCLC patients, peripheral
whole blood was drawn in EDTA tubes (Fisher Scientific). Within 3 hours of collection,
blood samples were centrifuged at 1,600 × g at room temperature for 10 minutes with the
brake off. Next, the plasma was transferred to a 15-mL conical tube without disturbing the
cellular layer and centrifuged at 3,000 × g at room temperature for 10 minutes with the
brake off. This step was repeated with a fresh 15-mL conical tube. The plasma was then
stored at -80 °C until analysis. Biopsy results, computed tomography, and/or magnetic
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resonance imaging records were used to determine sites of metastasis in PDAC patients
and NSCLC patients whose plasma samples were used for assessment of SAA levels. Liver
specimens from normal donors were obtained by percutaneous liver biopsy, and acquisition
of liver specimens from patients with liver metastases was previously described155. Liver
specimens from CRC patients with liver metastases were obtained from the Cooperative
Human Tissue Network (CHTN). Patient characteristics are shown in Table 4.1.

Cell lines
PDA.69 and PDA.8572 cell lines were previously described in Chapter 3. MC-38
cell line, which was used for orthotopic implantation, was purchased from Kerafast. Cell
lines were cultured in DMEM (Corning) supplemented with 10% fetal bovine serum (FBS,
VWR), 83 µg/mL gentamicin (Thermo Fisher), and 1% GlutaMAX (Thermo Fisher) at 37
°C, 5% CO2. Only cell lines that had been passaged less than 10 times were used for
experiments, and trypan blue staining was used to ensure that cells with > 95% viability
were used for studies. Cell lines were tested routinely for Mycoplasma contamination at
the Cell Center Services Facility at the University of Pennsylvania.

Animal experiments
Orthotopic implantation and intraportal injection of pancreatic tumor cell lines were
previously described in Chapter 3. For orthotopic implantation of colorectal tumor cells,
wild type mice were first subcutaneously injected with MC-38 (1 × 106 cells suspended in
100 µL of sterile PBS) on the right flank. After 10 days, mice were euthanized, and
subcutaneous tumors were collected. Tumors were then cut into small pieces, each 3 × 3
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mm in size, and placed in sterile PBS on ice until implantation. Mice were anesthetized
using isoflurane, and their abdomen was sterilized. Following administration of analgesic
agents, median laparotomy was performed as described above. Implantation of colorectal
tumor tissues into the cecum was then performed as previously described156. After placing
the intestines back into the peritoneal cavity, the peritoneum and skin were closed with a
suture, and mice were given buprenorphine as previously described in Chapter 3.
For hydrodynamic injection, 1 µg of pLIVE expression vectors were suspended in
sterile saline corresponding to 8% of mouse body weight as previously described149.
Vectors were injected into the portal vein via a 27-gauge needle within 5-8 seconds.
Successful injection was confirmed by complete blanching and swelling of the liver. For
both procedures, a sterile gauge was then held over the injection site for 1 minute to ensure
that no injected contents would leak into the peritoneal cavity. Afterwards, the intestines
were placed back into the peritoneal cavity, and the peritoneum and skin were closed with
a suture and autoclips, respectively. Following surgery, mice were given buprenorphine
subcutaneously as previously described in Chapter 3. For induction of liver injury, mice
were intraperitoneally injected with CCl4 (Sigma, 1 mL/kg of body weight) dissolved in
sunflower seed oil as previously described124.
For parabiotic joining of mice, female CD45.2 mice were orthotopically injected
with sterile PBS or pancreatic tumor cells as described above and co-housed with agematched female B6 CD45.1 mice. Each parabiotic pair was housed in a separate cage to
maximize bonding between partners. After one week, parabiotic partners were anesthetized
using continuous isoflurane, and their flanks were sterilized. After administration of
analgesic agents, longitudinal skin flaps from the lower limb to the upper limb were created,
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and everted skin flaps were sewn using a suture. In addition, the knees and olecranons of
parabiotic partners were joined together using a suture for additional stabilization.
Following surgery, mice were given buprenorphine subcutaneously at a dose of 0.05-0.1
mg/kg every 4-6 hours for 5 days.

Microscopic analysis
Mouse organs were processed as previously described in Chapter 3. Manual and
automated immunohistochemistry, immunofluorescence, and RNA in situ hybridization
were performed and analyzed as previously described in Chapter 3. Manual
immunohistochemistry of mouse tissues for SAA was previously described157. Detailed
information on antibodies and reagents used in experiments can be in found in Table 4.2.

Flow cytometry
Peripheral blood samples were obtained from the tail vein as previously
described129. Samples were resuspended in ACK lysing buffer (Life Technologies) at room
temperature for 15 minutes to remove red blood cells. After washing three times with
DMEM, cells were counted and stained using Aqua dead cell stain kit (Life Technologies)
following manufacturer’s protocol. For assessment of chimerism in parabiotically joined
mice, cells were washed three times with PBS containing 0.2 mM EDTA with 2% FBS and
stained with anti-CD45.1 and anti-CD45.2 antibodies (BioLegend) for 30 minutes at 4 °C
in the dark. Cells were then washed three times with PBS containing 0.2 mM EDTA with
2% FBS and examined using a FACS Canto II (BD Biosciences). FlowJo (FlowJo, LLC,
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version 10.2) was used to analyze flow cytometric data. Detailed information on antibodies
and reagents used in experiments can be in found in Table 4.2.

Detection of IL-6, SAA, and TIMP1
IL-6 levels in mouse serum samples were measured using cytometric bead array
(BD Biosciences), and data were analyzed using FCAP Array (BD Biosciences, version
3.0) as previously described in Chapter 3. SAA and TIMP1 levels in mouse serum samples
were measured using a commercially available enzyme-linked immunosorbent assay kit
(Thermo Fisher) following manufacturer’s protocol. Similarly, SAA levels in plasma
samples collected from normal donors and PDAC patients as described under “Clinical
Samples” were measured using a commercially available human enzyme-linked
immunosorbent assay kit (Thermo Fisher) following manufacturer’s protocol.

RNA and quantitative real-time PCR
RNA isolation from mouse organs, cDNA synthesis, and quantitative real-time
PCR were performed as previously described in Chapter 3. Primers used in experiments
and their sequences can be found in Table 4.3.

Statistical analysis
Statistical significance was calculated using Prism (GraphPad Software, version 7).
Multiple comparisons testing was performed using one-way ANOVA with Dunnett’s test.
Paired and unpaired group comparisons testing was carried out using Wilcoxon matchedpairs signed rank test and Mann-Whitney test, respectively. Comparison of Kaplan-Meier
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overall survival curves was performed using log-rank (Mantel-Cox) test. P values less than
0.05 were treated as significant. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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Figures and figure legends
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Figure 4.1 | STAT3 signaling in hepatocytes regulates SAA production in the setting
of primary PDAC development. a, Study design (n = 5 for both groups of mice injected
with PBS and PDAC (PDA.69)). b, Representative images of SAA detected by
immunohistochemistry. Dashed lines and asterisks indicate sinusoids and hepatocytes,
respectively. c, Study design (n = 4 for Stat3flox/flox mice injected with PBS and PDAC cells
(PDA.69); n = 8 and 7 for Stat3flox/flox Alb-Cre mice injected with PBS and PDAC cells
(PDA.69), respectively). d, mRNA levels of Saa. e, Representative images of Saa. Dashed
lines and asterisks indicate sinusoids and hepatocytes, respectively. f, Concentration of
circulating SAA. g, Representative images of Saa detected by RNA in situ hybridization.
Scale bars, 50 µm. Data representative of one experiment (a, b, and g) or two independent
experiments (c-f).
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Figure 4.2 | SAA is a critical determinant of liver metastasis. a, Concentration of
circulating SAA in normal donors (n = 69), patients with locally advanced PDAC (n = 28),
and patients with liver metastases (n = 43). Data represented as a box plot (center line,
median; box limits, upper and lower quartiles; whiskers, max and min values). b,
Representative images of SAA (brown) in the liver of normal donors (top) and patients
with liver metastases (bottom). Dashed lines and asterisks indicate sinusoids and
hepatocytes, respectively. Scale bars, 50 µm. c, Study design (n = 5 for all groups of mice
injected with PBS and PDAC cells (PDA.69)). d, Quantification of pSTAT3+ cells,
myeloid cells, and FN. e, mRNA levels of Saa. f, Study design (n = 4 and 5 for Saa+/+ mice
injected with PBS and PDAC cells (PDA.69), respectively; n = 5 and 6 for Saa-/- mice
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injected with PBS and PDAC cells (PDA.69), respectively). All groups of mice were
injected with PDAC-YFP cells (PDA.8572) on day 10. g, Representative images and flow
cytometric analysis. Scale bars, 1 cm. h, Quantification of PDAC-YFP cells. Data
representative of two independent experiments (c-h). *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 by Mann-Whitney test or one-way ANOVA. Data represented as mean ±
s.d. unless indicated otherwise.
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Figure 4.3 | Hepatocyte activation and SAA expression in PDAC patients with liver
metastases. a, Representative images of pSTAT3 (purple) and SAA (yellow) in the liver
of normal donors and patients with liver metastases. Dashed lines and asterisks indicate
sinusoids and hepatocytes, respectively. Scale bars, 50 µm. b, Kaplan-Meier overall
survival for patients with liver metastases with low (< 250 µg/mL, black, n = 21) and high
(> 250 µg/mL, red, n = 22) levels of circulating SAA. Mantel-Cox test was used to calculate
the P value.
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Figure 4.4 | SAA induces myeloid cell recruitment and fibrosis within the liver during
tumor development. a, Concentration of circulating SAA in patients with locally
advanced non-small cell lung carcinoma (NSCLC, n = 8) and patients with liver metastases
(n = 13). Data represented as a box plot (center line, median; box limits, upper and lower
quartiles; whiskers, max and min values). b, Representative images of SAA (yellow) in the
liver of CRC patients with liver metastases. Dashed lines and asterisks indicate sinusoids
and hepatocytes, respectively. Scale bars, 50 µm. c, Study design (n = 5 and 4 for Saa+/+
mice injected with PBS and CRC cells (MC-38), respectively; n = 4 and 5 for Saa-/- mice
injected with PBS and CRC cells (MC-38), respectively). d, Quantification of myeloid
cells and FN. Data representative of one experiment (c, d). *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001 by Mann-Whitney test or one-way ANOVA. NS, not significant.
Data represented as mean ± s.d.
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Figure 4.5 | SAA promotes the formation of a pro-metastatic niche in the liver. a,
Representative images of pSTAT3+ cells, myeloid cells, and FN. Saa+/+ and Saa-/- mice
were orthotopically injected with PBS or PDAC cells (PDA.69) (n = 5 for all groups of
mice), and the liver and pancreas/primary tumor were harvested after 20 days. Arrows
indicate Ly6G+ cells. b, Representative images of sinusoids (brown, stained with CD31) in
the liver. c, mRNA levels of Lcn2, S100a8, S100a9, Ccl6, Cxcl1, and Fn1 in the liver. Data
representative of two independent experiments (a-c). d, Representative images of the
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pancreas and primary tumor stained with CD31 (brown), CK19 (yellow), and Ki-67
(purple). e, Quantification of the weight of pancreas/primary tumor (left), number of Ki67+ tumor cells (middle), and vascular area (right). Data representative of one experiment
(d, e). f, Study design (n = 5-8 for all groups of mice injected with PBS and PDAC cells
(PDA.69)). All groups of mice were injected with PDAC-YFP cells (PDA.8572) on day
10. g, h, Representative images of the liver showing metastatic lesions (yellow, stained
with CK19) and Ki-67 (purple). Scale bars, 4 mm (g) and 200 µm (h). i, Quantification of
lesions (top) and Ki-67+ tumor cells (bottom). Data pooled from two experiments (f-i).
Scale bars, 50 µm unless indicated otherwise. *P < 0.05, **P < 0.01, ***P < 0.001, ****P
< 0.0001 by one-way ANOVA. NS, not significant. Data represented as mean ± s.d.
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Figure 4.6 | SAA is a downstream mediator of IL-6 signaling that drives myeloid cell
accumulation and fibrosis within the liver. a, Study design (n = 5 for all groups, except
n = 4 for Saa-/- mice). b, Concentration of IL-6 in the serum collected from control mice
(left), Il-6-/- mice (middle), and Saa-/- mice (right) on indicated days. Dashed lines indicate
the lower limit of detection. c, Representative images and quantification of pSTAT3+ cells,
myeloid cells, and FN. Arrows indicate Ly6G+ cells. Scale bars, 50 µm. Data representative
of one experiment (a-c). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by MannWhitney test or one-way ANOVA. NS, not significant. Data represented as mean + s.d. or
mean ± s.d.
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Figure 4.7 | SAA promotes myeloid cell accumulation and fibrosis in the setting of
liver injury. a, Study design (n = 5 for all groups, except n = 4 for Saa-/- mice injected with
CCl4). b, Representative images and quantification of myeloid cells and FN. Arrows
indicate Ly6G+ cells. Scale bars, 50 µm. Data representative of one experiment (a, b). *P
< 0.05, ***P < 0.001, ****P < 0.0001 by one-way ANOVA. NS, not significant. Data
represented as mean ± s.d.
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Figure 4.8 | IL-6/STAT3/SAA signaling axis does not impact expression of MIF and
TIMP1. a, Study design (n = 5 and 4 for mice injected with PBS and PDAC cells (PDA.69),
respectively). b, c, Representative images of CK19 (yellow) and TIMP1 (purple) in the
pancreas, primary tumor, and liver. Data representative of at least three independent
experiments (a-c). d, FPKM values of genes in the liver of control mice and NTB KPC
mice obtained from QuantSeq 3’ mRNA sequencing. Data represented as box plots (center
line, median; box limits, upper and lower quartiles; whiskers, max and min values). e, i, m,
Study designs. For e, n = 5-6 for Il-6+/+ mice injected with PBS and PDAC cells (PDA.69),
respectively; n = 4 and 5 for Il-6-/- mice injected with PBS and PDAC cells (PDA.69),
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respectively. For i, n = 5 for all groups, except n = 4-5 for Saa+/+ injected with PDAC cells
(PDA.69). For m, n = 4 for Stat3flox/flox injected with PBS and PDAC cells (PDA.69); n =
8 and 7 for Stat3flox/flox Alb-Cre mice injected with PBS and PDAC cells (PDA.69),
respectively. f, j, n, mRNA levels of Mif and Timp1 in the pancreas and primary tumor
relative to Actb. g, k, o, Representative images of CK19 (yellow) and TIMP1 (purple) in
the pancreas and primary tumor. h, l, p, Concentration of TIMP1 in the serum. Data
representative of one experiment (d-p). *P < 0.05, **P < 0.01 by Mann-Whitney test or
one-way ANOVA. NS, not significant. ND, not detected. Data represented as mean ± s.d.
unless indicated otherwise.
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Figure 4.9 | Primary PDAC development induces a systemic response that promotes
the formation of a pro-metastatic niche in the liver. a, Study design (n = 4 and 8 for
CD45.2 mice injected with PBS (group 1) or PDAC cells (PDA.69) (group 2), respectively).
SN, supernatant. b, Assessment of chimerism in parabiotically joined mice. Representative
flow cytometric analysis of the peripheral blood is shown. Boxed areas in flow cytometric
plots indicate representative gating and CD45.1+ and CD45.2+ cells as a percentage of
CD45+ cells. c, Dorsal (top) and ventral (bottom) views of parabiotically joined mice. †,
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site of laparotomy for orthotopic injection; ‡, skin suture for parabiotic joining. d,
Representative images and quantification of myeloid cells and FN. Arrows indicate Ly6G+
cells. Scale bars, 50 µm. e, mRNA levels of Saa. f, Concentration of IL-6 in pancreas
supernatant and serum collected from group 1. g, Concentration of IL-6 in pancreatic
tumor/pancreas supernatant and serum collected from group 2. Solid lines indicate data
points from individual mice (f, g). Dashed lines indicate the lower limit of detection (f, g).
h, Concentration of circulating SAA. Data representative of two independent experiments,
except f-h, which are representative of one experiment. *P < 0.05, **P < 0.01 by MannWhitney test or Wilcoxon test. NS, not significant. Data represented as box plots (center
line, median; box limits, upper and lower quartiles; whiskers, max and min values) unless
indicated otherwise.
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Figure 4.10 | IL-6/STAT3/SAA signaling axis does not impact the formation of a prometastatic niche in the lung. a, Representative images of myeloid cells and FN in the lung
of control mice, NTB KPC mice, and TB KPC mice (n = 5 for all groups). Scale bars, 50
µm. b, Quantification of myeloid cells and FN. c, Study design (n = 4 and 5 for Il-6+/+ mice
injected with PBS and PDAC cells (PDA.69), respectively; n = 5 and 4 for Il-6-/- mice
injected with PBS and PDAC cells (PDA.69), respectively). d, Quantification of myeloid
cells and FN. e, Study design (n = 5 for all groups of mice injected with PBS and PDAC
cells (PDA.69)). f, Quantification of myeloid cells and FN. g, Study design (n = 4 for
Stat3flox/flox mice injected with PBS and PDAC cells (PDA.69); n = 8 and 7 for Stat3flox/flox
Alb-Cre mice injected with PBS and PDAC cells (PDA.69), respectively). h,
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Quantification of myeloid cells and FN. i, Study design (n = 4 for all groups of mice
injected with PBS and PDAC cells (PDA.69)). All groups of mice were injected with
PDAC-YFP cells (PDA.8572) on day 10. j, Quantification of PDAC-YFP cells. Data
representative of one experiment (a-j). *P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001 by one-way ANOVA. NS, not significant. Data represented as mean ± s.d.
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Figure 4.11 | Conceptual model. IL-6 released from non-malignant cells in the pancreas
distributes to the liver through the portal vein and activates STAT3 signaling in hepatocytes.
Activated hepatocytes in turn produce SAA, which induces the accumulation of myeloid
cells and deposition of extracellular matrix proteins, to establish a pro-metastatic niche in
the liver. P, phosphorylation.
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Table 4.1 | Normal donor and patient characteristics. a, Characteristics of normal
donors, PDAC patients, and NSCLC patients whose plasma samples were used for
assessment of circulating SAA levels. b, Characteristics of normal donors and PDAC
patients whose liver specimens were used for assessment of SAA production.
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Table 4.2 | Antibodies, probes, and reagents used in experiments. AP, alkaline
phosphatase; DAB, 3,3’-diaminobenzidine; FAM, fluorescein amidite; FCM, flow
cytometry;

HRP,

horseradish

peroxidase;

IF,

immunofluorescence;

IHC,

immunohistochemistry; ISH, in situ hybridization; NP, nitropyrazole. N/A, not applicable.

120

Table 4.3 | Primer sequences.
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CHAPTER 5: Discussion and Future Experiments
Downstream effectors of IL-6/STAT3/SAA signaling
Serum amyloid A1 and A2 (SAA) are acute-phase reactants that are predominantly
produced by hepatocytes. Earlier studies on SAA focused on elucidating the capacity of
SAA to induce migration of myeloid cells using in vitro assays and models of systemic
infection158. However, elevated levels of circulating SAA are also associated with primary
tumorigenesis as well as metastatic disease. A role for SAA in promoting metastatic spread
of malignant cells to the liver—which may, at least in part, form the basis for metastatic
tropism of PDAC—is only now starting to be elucidated.
In Chapters 1 and 2, we discussed that pancreatic ductal adenocarcinoma (PDAC)
is a uniformly lethal disease that most commonly metastasizes to the liver. The LSLKrasG12D/+;LSL-Trp53R127H/+;Pdx-1-Cre (KPC) mouse model of PDAC and cell lines
derived from this model provides a platform for studying the impact of primary tumor
development on the liver. In Chapter 3, we identified hepatocytes as a critical determinant
of the formation of a pro-metastatic niche in the liver. Myeloid cell accumulation and
fibrosis, which are the two defining features of a pro-metastatic niche, are dependent on
interleukin 6 (IL-6)/ Signal Transducer and Activator of Transcription 3 (STAT3) signaling
in hepatocytes. In Chapter 4, our studies revealed that SAA are downstream mediators of
IL-6/STAT3 signaling in hepatocytes. SAA engenders myeloid cell accumulation and
fibrosis within the liver, and genetic ablation of Saa inhibits the formation of a prometastatic niche. In this chapter, we further explore mechanisms by which SAA regulates
the function of liver-resident cells to promote metastatic spread of malignant cells and
discuss roles that SAA may have in cancer immunosurveillance.
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Myeloid cells.
Myeloid cell accumulation is a defining feature of the pro-metastatic niche in
distant organs, including the lung and liver. Within this niche, myeloid cells release
inflammatory cytokines, growth factors, and proangiogenic molecules that suppress antitumor immune responses and support tumor cell seeding and growth. Recent studies have
implicated myeloid cells as a key determinant of metastasis in experimental models of
melanoma, breast cancer, lung cancer, and gastrointestinal malignancies13. Understanding
mechanisms that regulate myeloid cell recruitment to distant organs, therefore, is critical
to developing more effective strategies to inhibit the formation of a pro-metastatic niche.
Our studies demonstrate that SAA induces myeloid cell accumulation within the liver, yet
additional studies are needed to identify myeloid cell receptors for SAA and understand
the impact of SAA on myeloid cell function.
To date, six receptors for SAA have been identified144,158. These include: Toll-like
receptors 2 and 4 (TLR2 and 4), formyl peptide receptor 2 (FPR2), P2X purinoceptor 7
(P2RX7), scavenger receptor class B type 1 (SCARB1), and advanced glycosylation end
product-specific receptor (AGER). We hypothesized that primary PDAC development may
increase expression levels of these receptors in the liver in a SAA-dependent manner. To
test this, Saa+/+ mice and Saa-/- mice were orthotopically injected with PBS or PDAC cells,
and expression levels of the six known receptors for SAA in the liver were examined using
quantitative real-time PCR (Fig. 5.1a). Primary tumor development increased expression
levels of TLR2 in the liver, yet in the absence of SAA, TLR2 expression remained
unchanged (Fig. 5.1b). FPR2, and P2RX7 expression levels in the liver increased to a lesser
extent in response to primary tumor development, and these changes did not meet statistical
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significance. Based on a previous study demonstrating that engagement of TLR2 by SAA
induces activation of NF-κB signaling159, we also evaluated the liver for phosphorylated
p65 (p-p65), which is a marker of NF-kB signaling, using immunohistochemistry (Fig.
5.2a). Consistent with the notion that SAA activates NF-kB signaling, tumor implanted
Saa-/- mice displayed significantly fewer F4/80+ myeloid cells that were positive for p-p65
compared to Saa+/+ mice (Fig. 5.2b). Intriguingly, p-p65 was detected on F4/80- cells lining
sinusoidal spaces, suggesting that SAA may activate not only myeloid cells but other liverresident cells, including hepatic stellate cells and endothelial cells.
In future studies, it will be important to further dissect a role for TLR2 signaling in
forming a pro-metastatic niche in the liver through animal model studies and in vitro assays.
To do this, mice that lack TLR2 specifically in myeloid cells (Tlr2flox/flox Lyz2-Cre or
Tlr2flox/flox Cd11b-Cre) could be orthotopically implanted with PBS or PDAC cells. This
would provide insights into the role of TLR2 on myeloid cells in regulating the formation
of a pro-metastatic niche—namely, myeloid cell accumulation and fibrosis—as well as the
susceptibility to metastatic colonization. Bone marrow-derived macrophages generated
from Tlr2+/+ or Tlr2-/- mice could also be used to study the impact of SAA on myeloid cell
function, including production of inflammatory cytokines and chemokines and capacity to
migrate in chemotaxis assays. Overall, studies designed to elucidate mechanisms
underlying SAA/TLR2-mediated regulation of myeloid cell function would further define
key mediators of cancer metastasis and identify therapeutic targets.

124

Hepatic stellate cells.
Representing 10% of all liver-resident cells in the normal liver, hepatic stellate cells
are quiescent, vitamin-A-storing cells that are located in the subendothelial space of Disse.
Under inflammatory conditions, these cells transdifferentiate into proliferative, fibrogenic
myofibroblasts and are now well-established to be a key driver of fibrosis in experimental
models of liver injury and human liver diseases. A key activator of hepatic stellate cells is
transforming growth factor beta (TGF-β), which promotes activation of SMAD proteins as
well as mitogen-activated protein kinase (MAPK) signaling in hepatic stellate cells160. As
previously discussed in Chapter 1, TGF-β has recently been proposed by Costa-Silva et al.
to have a key role in establishing a pro-metastatic niche in the liver14. After taking up
exosomes released by pancreatic tumor cells, liver-resident macrophages secreted TGF-β,
which induced hepatic stellate cells to deposit fibronectin. This process established a niche
that attracted myeloid cells and enhanced tumor cell colonization in the liver. In addition
to TGF-β, tissue inhibitor of metalloproteinases 1 (TIMP1) has been implicated as an
activator of hepatic stellate cells by Grünwald et al18. Genetic ablation of Timp1 and its
receptor Cd63 effectively prevented activation of hepatic stellate cells and in doing so,
reduced the susceptibility of the liver to metastatic spread. Collectively, these studies
revealed a role for hepatic stellate cells in establishing a pro-metastatic niche in the liver.
Based on observations by Costa-Silva et al. and Grünwald et al., we hypothesized
that hepatic stellate cells may also be a downstream effector of IL-6/STAT3/SAA signaling.
To test this hypothesis, Saa+/+ mice and Saa-/- mice were orthotopically injected with PBS
or PDAC cells, and expression levels of desmin, an activation marker of hepatic stellate
cells, in the liver were examined using immunohistochemistry (Fig. 5.3a). We found that
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primary PDAC development increased expression levels of desmin in the liver, but genetic
ablation of Saa inhibited this process (Fig. 5.3b, c). Our results are consistent with a recent
study highlighting a role for SAA in activating hepatic stellate cells148. In this study, in
vitro stimulation of primary human and rat hepatic stellate cells with recombinant SAA
activated NF-κB and c-Jun N-terminal kinase (JNK) signaling, which induced chemokine
production and proliferation of hepatic stellate cells. These results, taken together with our
findings that SAA engenders activation of hepatic stellate cells in the setting of PDAC,
suggest that SAA may be a key determinant of hepatic stellate cell activation and function.
Future studies should focus on identifying receptors for SAA on hepatic stellate
cells and further dissecting the impact of SAA on hepatic stellate cell function. One
promising target is TLR2, which has been shown to be critical for fibrogenesis in
experimental models of non-alcoholic steatohepatitis161 and CCl4-induced liver injury162.
To study a role for TLR2 in regulating the impact of SAA on hepatic stellate cells, primary
hepatic stellate cells could be isolated from the liver of Tlr2+/+ and Tlr2-/- mice and
stimulated with recombinant SAA in vitro. Production of chemokines as well as
extracellular matrix proteins could be examined using quantitative real-time PCR and
immunohistochemistry. Hepatic stellate cell lines LX1 and LX2163 could also be used to
further support findings from primary hepatic stellate cells. In addition, mice that lack
TLR2 specifically in myofibroblasts (Tlr2flox/flox Acta2-Cre) could be utilized to elucidate
a role for TLR2 on hepatic stellate cells in establishing a pro-metastatic niche in the liver
as well as enhancing the susceptibity of the liver to metastatic colonization. Overall, these
studies would define mechanisms underlying SAA-mediated regulation of hepatic stellate
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cell function and more broadly, provide insight into a role for hepatic stellate cells in
establishing a pro-metastatic niche in the liver.

T cells.
A notable feature of PDAC is a desmoplastic reaction that is accompanied by a
leukocyte infiltrate. As previously discussed in Chapter 2, this immune infiltrate consists
primarily of myeloid cell subsets, while effector T cells are largely absent. Because of this
lack of effector T cells, PDAC is believed to exhibit “immune privilege” that protects
malignant cells from anti-tumor responses85. To date, only a handful of studies have
identified chemokines that may contribute to immune privilege in PDAC. These include
CXCL1164, CXCL5165,166, and CXCL1250, which can be secreted by malignant cells or
carcinoma-associated fibroblasts and inhibit T cell entry into the primary tumor. Cell types
that reside outside of the tumor have also been implicated in regulating T cell infiltration
into PDAC. Depletion of granulocytes or extratumoral macrophages induced robust T cell
accumulation within the primary tumor52,167, with the latter strategy rendering the tumor
more sensitive to CD40 agonists. These findings suggest that immune cells residing outside
the primary tumor are actively involved in cancer immunosurveillance. Despite these
recent studies, our understanding of mechanisms underlying T cell exclusion from the
tumor microenvironment remains incomplete.
Chemotactic properties of SAA have been studied most extensively in myeloid cells
as described above, but SAA has also been proposed to regulate migration of T cells168.
Based on this finding, we hypothesized that SAA may also regulate T cell migration in the
setting of PDAC. To test this, Saa+/+ mice and Saa-/- mice were orthotopically injected with
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PDAC cells, and the presence of CD4+ and CD8+ T cells within the primary tumor was
examined (Fig. 5.4a). As expected, Saa+/+ mice displayed a low number of CD4+ and CD8+
T cells within the primary tumor, but the primary tumor in Saa-/- mice contained a
significantly higher number of CD4+ and CD8+ T cells (Fig. 5.4b, c). These results
demonstrate that SAA inhibits recruitment of T cells into the primary tumor. We did not
observe any difference in the number of Ki-67+ cells between Saa+/+ mice and Saa-/- mice
(Fig. 5.4b, c), suggesting that additional mechanisms, including T cell exhaustion, may
regulate the capacity of T cells to inhibit tumor growth and/or kill tumor cells.
Consistent with our findings in the primary tumor, genetic ablation of Saa also
increased CD4+ and CD8+ T cell accumulation in metastatic lesions (Fig. 5.5a, b).
Intriguingly, metastatic lesions in tumor bearing Saa+/+ mice contained a fewer number of
T cells compared to non-tumor bearing Saa+/+ mice (Fig. 5.5b). Following this observation,
we hypothesized that expression levels of SAA may be lower in the liver of non-tumor
bearing Saa+/+ mice. To test this, we examined for the presence of Saa mRNA in the liver
using RNA in situ hybridization. We detected diffuse SAA expression in the liver of tumor
bearing Saa+/+ mice, whereas non-tumor bearing mice displayed Saa mRNA only in
hepatocytes that were in direct contact with CK19+ malignant cells. These results suggest
that SAA synthesized by hepatocytes in response to primary PDAC development may act
as a “repellent” that prevents T cells from engaging metastatic lesions.
In future studies, it will be important to identify mechanisms underlying SAAmediated regulation of T cell function. To determine the impact of SAA on the capacity of
T cells to migrate, expression levels of chemokine receptors on T cells in Saa+/+ mice and
Saa-/- mice could be evaluated using flow cytometry and immunohistochemistry. In this
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analysis, T cells in the primary tumor, metastatic lesions, as well as lymphoid organs could
be examined to determine whether SAA affects T cells only within tumor tissues versus
distant organs. T cells could also be incubated with or without recombinant SAA in vitro,
and their capacity to migrate assessed using chemotaxis assays. In addition to altering
migratory properties of T cells, SAA may inhibit T cells from killing tumor cells. To test
this, expression levels of immunomodulatory molecules, including PD-1, and granzymes
on T cells in Saa+/+ mice and Saa-/- mice could be evaluated using flow cytometry and
immunohistochemistry as described above. Further, T cells incubated with or without
recombinant SAA in vitro could be co-cultured with luciferase-expressing PDAC cells,
and tumor cell death measured using luciferase assay system. Taken together, these studies
would provide insight into regulation of T cell function by SAA.

Therapeutic and diagnostic approaches to liver metastasis
Metastatic disease is a leading cause of morbidity and mortality in cancer patients
and frequently affects the liver. Liver metastasis is especially common in PDAC, affecting
nearly 70% of patients3. Our studies reveal that IL-6/STAT3/SAA signaling in hepatocytes
is a critical determinant of liver metastasis and forms the basis for the formation of a prometastatic niche in the liver. While we have focused our studies on PDAC, our data suggest
that IL-6/STAT3/SAA signaling may also have a pivotal role in regulating liver metastasis
in other types of malignancy, including colorectal carcinoma (CRC) and non-small cell
lung carcinoma. Hence, IL-6/STAT3/SAA signaling is an attractive therapeutic target not
only for PDAC and but also for other malignancies that frequently metastasize to the liver.
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Hepatocyte-directed formation of a pro-metastatic niche in the liver presents
multiple points of intervention (Fig. 5.6). First, IL-6 that is released into the circulation by
the primary tumor may be inhibited by antibodies that target IL-6 receptor (IL-6R). This
strategy is supported by our findings demonstrating that blockade of IL-6R inhibits the
formation of a pro-metastatic niche in the liver (Fig. 3.10). IL-6 may also be neutralized by
antibodies that directly bind this cytokine, such as siltuximab169. Second, STAT3 signaling
in hepatocytes may be targeted using STAT3 inhibitors. However, the lack of specificity
and toxicities associated with currently available STAT3 inhibitors are likely to limit
clinical benefits of these therapeutics170. Molecules that specifically target downstream
effectors of STAT3 signaling, including Janus kinase 1 (JAK1) inhibitor itacitinib171, offer
an alternative means to inhibiting STAT3 signaling with high specificity. These therapeutic
modalities may be particularly beneficial to patients who have an early stage disease, when
key elements of a pro-metastatic niche are being formed in the liver. For patients with
resectable tumors, blockade of IL-6/STAT3/SAA signaling in a neo-adjuvant or adjuvant
setting may inhibit recurrence of cancer in the liver.
Beyond IL-6/STAT3/SAA signaling in hepatocytes, fibrosis and myeloid cell
accumulation that occur in the liver also present therapeutic opportunities. One promising
approach to reversing liver fibrosis is inhibition of focal adhesion kinase (FAK). In a recent
study, FAK was shown to activate hepatic stellate cells in vitro and in experimental models
of liver injury in a TGF-β1-dependent manner172. Intriguingly, FAK was also demonstrated
to regulate fibrosis within the primary PDAC173. Inhibition of FAK using small molecule
VS-4718 reduced tumor fibrosis, slowed tumor progression, and decreased the number of
immunosuppressive myeloid cells within the primary tumor. This therapy also rendered
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PDAC more responsive to immunotherapies, including adoptive T cell transfer and PD-1
antagonists. Taken together, FAK inhibition presents an opportunity to target fibrosis—
and even myeloid cells—within the primary tumor as well as metastatic sites.
CD40 agonists offer yet another strategy to preventing and/or reversing liver
fibrosis. Our laboratory has previously demonstrated that CD40 agonists decrease fibrosis
within the primary PDAC by inducing recruitment of Ly6C+ CCR2+ monocytes that shift
the expression profile of matrix metalloproteinases (MMP) within the primary tumor46,129.
Future studies in our laboratory will define the impact of CD40 agonists on extracellular
matrix proteins, expression levels of MMPs, and myeloid cell recruitment in the liver. In
addition, SAA and myeloid chemoattractants that are induced by IL-6/STAT3/SAA
signaling (Fig. 3.1f and Table 3.1) may be targeted to prevent myeloid cell accumulation
within the liver. While antibodies that bind SAA and myeloid chemoattractants, such as
lipocalin 2 (LCN2) and S100 proteins, are not yet available, these molecules are potential
therapeutic targets. Together, components of IL-6/STAT3/SAA signaling and downstream
effectors that establish a pro-metastatic niche in the liver present multiple points of
therapeutic intervention.
In addition to investigating strategies for the treatment of metastatic PDAC, future
studies should focus on evaluating the utility of SAA as a diagnostic and prognostic marker
of liver metastasis. Given that circulating levels of SAA correlate with disease progression
and worse overall survival (Figs. 4.2a and 4.3b), our studies suggest that SAA is a
promising marker of the primary as well as metastatic PDAC. Circulating levels of SAA
may also be evaluated in conjunction with other previously published markers of PDAC
for early detection of PDAC. Examples include CA19-9 and thrombospondin-2, which
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were recently shown to detect early PDAC with a specificity and sensitivity of 98% and
87%, respectively174. SAA, along with other markers of PDAC, may also be used to
identify a subset of locally advanced patients who are more prone to developing metastatic
disease in the liver and tailor more rigorous monitoring and treatment regimens.

Concluding remarks
The liver is the most common site of metastatic spread in cancer. In describing this
metastatic tropism in 1889, Stephen Paget stated that “he who turns over the records of
cases of cancer is only a ploughman, but his observation of the properties of the soil may
also be helpful150.” Our studies provide insight into mechanisms underlying hepatocytemediated formation of a fertile “soil” that supports cancer cell seeding and growth in the
liver. We also identify SAA as a key “nutrient” that is released by hepatocytes in response
to primary tumor development, which induces activation of IL-6/STAT3 signaling in
hepatocytes. Genetic ablation or blockade of components of IL-6/STAT3/SAA signaling
effectively inhibits the formation of a pro-metastatic niche and turns the liver into a barren
“soil.” Future studies should focus on further dissecting a role for SAA in regulating the
immunological function of liver-resident cells as well as evaluating therapeutic strategies
to inhibition the formation of a pro-metastatic niche in the liver. Additional acute-phase
reactants released by hepatocytes may also be involved in the formation of a pro-metastatic
niche in the liver and other distant organs. Together, our findings identify hepatocytes as a
key determinant of metastasis and a promising therapeutic target for the treatment of cancer.
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Materials and methods
Microscopic analysis
Mouse organs were processed as previously described in Chapter 3. Automated
immunohistochemistry and RNA in situ hybridization were performed and analyzed as
previously described in Chapter 3. Detailed information on antibodies and reagents used in
experiments can be in found in Table 5.1.

RNA and quantitative real-time PCR
RNA isolation from mouse organs, cDNA synthesis, and quantitative real-time
PCR were performed as previously described in Chapter 3. Primers used in experiments
and their sequences can be found in Table 5.2.

Statistical analysis
Statistical significance was calculated using Prism (GraphPad Software, version 7).
Multiple comparisons testing was performed using one-way ANOVA with Dunnett’s test.
Unpaired group comparisons testing was carried out using Mann-Whitney test. P values
less than 0.05 were treated as significant. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Figures and figure legends

Figure 5.1 | Primary PDAC development increases expression levels of TLR2 in the
liver. a, Study design (n = 5 for all groups). b, mRNA levels of SAA receptors Tlr2, Tlr4,
Fpr2, P2rx7, Scarb1, and Ager in the liver. Data representative of one experiment (a, b).
*P < 0.05 by one-way ANOVA. NS, not significant. Data represented as mean ± s.d.
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Figure 5.2 | SAA induces activation of NF-κB signaling in the liver. a, Study design (n
= 5 for all groups). b, Representative images of F4/80 (yellow) and p-p65 (purple) in the
liver. Scale bars, 100 µm. Data representative of one experiment (a, b).
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Figure 5.3 | SAA induces activation of hepatic stellate cells. a, Study design (n = 5 for
all groups). b, Representative images of desmin (brown) in the liver. Scale bars, 50 µm. c,
Quantification of desmin in the liver. Data representative of one experiment (a-c). ***P <
0.001 by one-way ANOVA. Data represented as mean ± s.d.
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Figure 5.4 | SAA inhibits T cell infiltration into the primary tumor. a, Study design (n
= 5 for all groups). b, Representative images of CD8 (brown), Ki-67 (yellow), and CD4
(purple) in the liver. Scale bars, 50 µm. c, Quantification of desmin in the liver. Data
representative of one experiment (a-c). *P < 0.05, **P < 0.01 by Mann-Whitney test. Data
represented as mean ± s.d.
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Figure 5.5 | SAA inhibits T cell infiltration into metastatic lesions in the liver. a, Study
design (n = 4-8 for all groups). b, Representative images of CK19 (yellow) and CD4
(purple) in the liver detected by immunohistochemistry. c, Representative images of CK19
(yellow) and Saa (purple) in the liver detected by dual immunohistochemistry and RNA in
situ hybridization. Scale bars, 50 µm. Dashed lines and asterisks indicate sinusoids and
hepatocytes, respectively. Data representative of one experiment (a-c).
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Figure 5.6 | Therapeutic targets. Hepatocyte-mediated formation of a pro-metastatic
niche in the liver presents multiple points of therapeutic intervention. Antibodies and small
molecules can be used to inhibit IL-6/STAT3/SAA signaling in hepatocytes as well as
downstream effectors. P, phosphorylation.
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Table 5.1 | Antibodies, probes, and reagents used in experiments. AP, alkaline
phosphatase; DAB, 3,3’-diaminobenzidine; HRP, horseradish peroxidase; IHC,
immunohistochemistry; ISH, in situ hybridization; NP, nitropyrazole. N/A, not applicable.
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Table 5.2 | Primer sequences.
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